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All four papers in this thesis utilize the Tromsø Study, a large population-based cohort with 
repeated health surveys (1-7). In paper I, we followed 26 855 participants from the inclusion in Tromsø 
4 (1994-95) throughout 2012, and assessed the biennial incidence rates of VTE. In Papers II-IV, patients 
with a first VTE in the period 1994-2012 derived from Tromsø 4 (Paper II) or Tromsø 1-6 (Papers III and 
IV) were followed from their first VTE until the date of recurrence, death or emigration, or the end of 
the study period, whichever came first. Paper IV additionally included data from the Multiple 
Environmental and Genetic Assessment of Risk Factors for venous thrombosis (MEGA) follow up study.  
 We found that the overall age-adjusted incidence of VTE increased by 27% from 1996 to 2012. 
The observed incremental trend was largely due to an increase in the rate of PE. Furthermore, we 
found that the rates of recurrence and mortality remained high, particularly during the first year after 
the VTE event. Among patients with hospital-related VTE, the reason for hospitalisation appeared to 
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into account, the risk estimates dropped substantially. Patients with a first VTE related to 
hospitalisation for medical illness had similar recurrence risk as patients with a non-hospital-related 
first VTE. Finally, we found that a history of MI was associated with increased risk of VTE recurrence, 
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1. Introduction  
1.1 Venous thromboembolism  
Thrombosis occurs when a blood clot (i.e. thrombus) is formed inside a blood vessel. Thrombosis may 
occur in arteries or in veins. A thrombosis in arteries predominantly results in myocardial infarction 
(MI) if cardiac supply is involved, ischemic stroke in case of cerebral involvement, and rarely ischemia 
in other locations if peripheral arteries are involved.  A thrombosis in a deep vein that interferes with 
normal venous blood flow back towards the heart is referred to as deep vein thrombosis (DVT). DVT 
commonly occurs in the large veins of the leg, thigh or pelvis, but it can also occur in other parts of the 
body, such as the upper extremities, inferior vena cava, portal- and mesenteric veins, or cerebral sinus 
veins. Classical signs and symptoms of DVT are swelling, tenderness, warmth and discolouration of the 
affected extremity. An embolus is a thrombus that dislodges from its original site and travels via the 
bloodstream through the right side of the heart and into the lungs. The embolus becomes lodged 
where the vessel narrows, and subsequently blocks the blood flow in a pulmonary artery. This 
condition is referred to as pulmonary embolism (PE). PE is a serious and life-threatening complication 
of DVT. Clinically, PE is characterized by dyspnoea, tachypnoea, pleuritic-chest pain, haemoptysis, and 
in severe cases, circulatory collapse and death. Venous thromboembolism (VTE), a collective term for 
DVT and PE, is a public health concern with substantial economic burden (1).  
Anticoagulant drugs are the main therapy for patients with VTE. For many years, standard 
treatment of VTE patients without cancer constituted an initial phase of low-molecular-weight heparin 
(LMWH) and a vitamin K antagonist (VKA) such as warfarin, followed by VKA in monotherapy for long-
term treatment (3-12 months). LMWH is the recommended treatment for VTE patients with cancer. 
Recent evidence indicates that direct oral anticoagulants (DOACs) including direct thrombin inhibitors 
(e.g. dabigatran) and factor (F) Xa inhibitors (e.g. rivaroxaban, edoxaban and apixaban) have similar 
efficacy on VTE recurrence and an additional advantage of less bleeding risk when compared with 
warfarin for the long-term treatment of VTE (2). Recently published guidelines from the American 
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College of Chest Physicians (ACCP) recommend DOACs over warfarin in acute and long-term treatment 
of VTE in patients without cancer (3). 
The first case of DVT was reported seven centuries ago (4), however, understanding into the 
aetiology and pathogenesis of VTE began in the mid-1800s. A German physician, Rudolph Virchow 
proposed in 1856 a triad of physiological alterations that increase the risk of VTE. He postulated three 
major contributors to the pathophysiology of thrombosis: stasis of blood (alterations in the blood 
flow), a state of hypercoagulability (changes of blood composition), and venous injury (changes of the 
vessel wall) (figure 1). This classification remains valid and continues to serve as the foundation of our 
understanding of the pathophysiological mechanism of VTE (5, 6).  
  
Figure 1. Virchow’s Triad 
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1.2 Pathogenesis of venous thromboembolism 
Autopsy and radiological studies have shown that venous thrombi originate near the vessel wall in the 
apex of the venous valve pocket, and that venous thrombi mainly contain red blood cells and fibrin (7). 
The venous valve pocket of the calf vein is prone to hypoxia (8) and a common location for the initiation 
of venous thrombi (figure 2).  
 
Figure 2. The pathology of DVT in the venous valves: The venous valvular sinus is a predilection site for 
thrombus formation. The vortical flow pattern at the venous valvular sinus leads to a steep decline in 
oxygen tension. The resultant hypoxia activates the venous endothelium, leading to the recruitment 
and binding of monocytes (Mc), platelets (Plt), and tissue factor (TF)-positive microparticles (MP). 
Consequently, TF from activated Mc and MP may activate the coagulation cascade and initiate 
thrombosis formation.  
 
Hypoxia is suggested to be associated with prothrombotic and proinflammatory processes 
within the endothelial cells (7, 8) and it has been hypothesized that hypoxia caused by blood stasis 
leads to the activation of endothelial cells. A healthy and undamaged endothelium is a metabolically 
active interface between blood and the underlying tissues. It prevents adherence of cells and proteins 
required for clotting, hence preventing thrombosis (9). The endothelium is activated by hypoxia and/ 
or inflammatory mediators. Activation of the endothelium results in expression of P-selectin and E-
selectin, which in turn facilitate adhesion of  leukocytes (monocytes), platelets and TF+ microvesicles 
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(MVs) on the surface of the endothelium (10) with subsequent activation of the coagulation cascade. 
The activation of the coagulation cascade overwhelms the protective anticoagulant pathways and 
triggers thrombus formation (7). Together, activated (a) factor VIIa and TF, trigger the extrinsic 
coagulation pathway via activation of FIX and FX through FVIII. Activated FX and FV convert 
prothrombin (FII) to thrombin (FIIa). Thrombin further converts fibrinogen (FI) to fibrin (FIa) and 
activates FXIII which ultimately leads to stabilized fibrin (7). In addition, injury to the endothelium 
results in expression of TF, exposure of the sub-endothelial vascular collagen to platelets and clotting 
factors, and adhesion of white blood cells to the endothelial surface (11).  
 
1.3 Epidemiology of incident venous thromboembolism 
1.3.1 Venous thromboembolism in the general population 
VTE is the third most common cardiovascular disease after MI and stroke, (12) and is a major cause of 
morbidity and mortality worldwide. VTE is a common condition with an overall incidence of 1 to 2 per 
1000 persons each year in Western countries (13, 14). The annual number of symptomatic VTE in 
Europe is more than one million (15). Additionally, approximately 0.3 million deaths occur annually 
due to sudden PE or following undiagnosed VTE (15), which is more than twofold the combined deaths 
due to acquired immune deficiency syndrome (AIDS), breast and prostate cancer, and transport 
accidents (15). 
DVT accounts for approximately two-thirds of all VTE events, whereas PE makes up nearly one-
third, although the two conditions often exist simultaneously (16, 17). Out of those presenting with 
symptomatic DVT, 50-80 % have silent PE (18), whereas, among individuals with symptomatic PE, 50% 
have asymptomatic DVT (19) . 
VTE has serious short and long-term complications. Short-term thrombosis sequelae include 
extension of the thrombus, early recurrence, and mortality. VTE is also associated with long-term 
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complications such as postthrombotic syndrome (PTS), chronic thromboembolic pulmonary 
hypertension (CTPH), late recurrence, and death (20, 21). Recurrent thrombosis is relatively common, 
particularly in patients with unprovoked VTE (22). Approximately 30% of patients develop recurrence 
within the next 10 years following a first VTE diagnosis (23). Anticoagulant-related major bleeding 
occurs in about 5-10% in the first year following an initial VTE diagnosis (24). For nearly one-fourth of 
PE patients, the initial clinical presentation is sudden death (20). Moreover, PE is estimated to be the 
leading preventable cause of death in hospitalized patients (25).  PTS is the most common complication 
of DVT, affecting between 20-50% of patients with lower limb DVT (21, 22).  Symptoms of PTS include 
pain, heaviness, cramps and persistent swelling of the affected extremity (21). Risk factors for 
development of PTS include female sex, obesity, proximal DVT, recurrent DVT and varicose veins (26). 
Prognosis mainly depends on the affected anatomic segment and time till restoration of vessel 
strength (21). PTS impairs patient mobility, quality of life and increases the risk of disability pension 
(21). Chronic obstruction of major pulmonary arteries results in CTPH that causes additional workload 
on the right side of the heart due to abnormally high blood pressure in the arteries. CTPH occurs in 
0.5-1.5% of all PE cases and in 1.5-4.0% of patients with unprovoked PE. The majority of the CTPH cases 
were identified within the first 2 years after the initial PE diagnosis (27).  
 
1.3.2 Time-trends in incidence rates of venous thromboembolism  
The reported incidence of an initial episode of VTE varies substantially in previous literature as it 
ranged between 62 and 143 per 100,000 individuals per year (13, 24, 28-32). The incidence of first-
time PE ranged between 19 and 80 per 100,000 per year, and incidence of first-time DVT ranged 
between 35 and 95 per 100,000 per year (13, 24, 28-32). These variations may be due to population 
characteristics such as age distribution, ethnicity, available data sources, case definition and validation 
procedures, study design, and dependence on hospital inpatient databases (13, 14, 16, 33, 34). 
Moreover, some other studies did not separate incident events from recurrent events or did not 
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include autopsy-identified events (35). Modification in risk factors, prevention strategies, increased 
awareness of VTE risk, and the use of thromboprophylaxis in high-risk situations can influence the rates 
of VTE in the community (36). For instance, the prevalence of VTE risk factors such as old age, obesity 
and cancer are increasing at the population level in Western countries (15, 34, 35). The widespread 
use of LMWH for VTE prophylaxis (24) as well as the introduction and utilization of more sensitive and 
objective diagnostic tools, such as multidetector row computed tomographic pulmonary angiography 
(CTPA) and magnetic resonance imagining (MRI) for detection of PE, may have influenced the rates 
during the last 20 years (37-39).  
Scientific literature describing the incidence of VTE vary considerably, and the majority of the 
population-based studies were carried out several decades ago (14, 20, 24, 25). Few studies have 
investigated recent time trends in the incidence of VTE. Two studies reported an 80% increase in the  
rates of VTE in the period 1985-2009 (39) and 1993-2006 (38) with a considerable increase from 1999 
to 2009, primarily due to an increase in PE (13, 38-40).  
To summarise, few studies have focused on the trend in VTE-incidence during the last decades. 
Increased awareness of VTE and a better understanding of VTE epidemiology may assist better public 
health outcomes through further research into VTE risk factors and targeted prevention.  
 
1.3.3 Classification of venous thromboembolism  
VTE events can be broadly categorized as being provoked (secondary/ environmental) or unprovoked 
(idiopathic/ non-environmental), depending on the presence of risk factors at the time of VTE 
diagnosis. This classification has implications for the risk of VTE recurrence and length of treatment 
(41). VTE events are categorized as provoked if they occur in the presence of either transient (e.g. 
hospitalization, acute medical illness, recent surgery, trauma, and long-haul travel) or persistent (e.g. 
active cancer, paralysis) provoking factors. Risk factors are further classified into major and minor. 
Provoked VTE events occur in the presence of major transient risk factors (e.g. major trauma, surgery 
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with general anaesthesia for more than 30 minutes, or acute illness with admission to hospital for at 
least 3 days) in the 3 months before an event. Minor transient risk factors include surgery with general 
anaesthesia for less than 30 minutes, acute illness with admission to hospital for less than 3 days, 
oestrogen therapy, and pregnancy in 2 months before a VTE diagnosis. When VTE occurs in patients 
with a minor transient risk factor, or occurs many months after a major risk factor, it can be 
controversial whether the risk factor is prognostically significant enough to justify categorization of the 
VTE as provoked. VTE events are considered unprovoked if they occur in the absence of a provoked 
factor, transient or persistent (41). 
 
1.3.4 Risk factors for venous thromboembolism  
In epidemiology, a risk factor is a characteristic (or exposure) that affects the incidence of disease and 
has a causal role in the development of disease (42, 43). Stasis, hypercoagulability, and alteration of 
the vessel wall (endothelial activation or injury) are the major factors responsible for thrombus 
formation and propagation according to Virchow's triad (44). Almost all risk factors for VTE fall into 
one or more categories of this triad. VTE is a complex and a multicausal disease associated with several 
risk factors, which must be present for an event to occur (45). 
The complex interplay between risk factors for VTE may be explained by the thrombosis 
potential model (45) (figure 3). This model is based on the assumption that each risk factor enhances 
the risk, called an individual’s thrombosis potential, and when the combined effect of these risk factors 




Figure 3. The Thrombosis potential model. The green line represents a heredity factor for VTE (e.g. 
Factor V Leiden), and the purple line represents the effect of a risk factor that increases over time (e.g. 
age). The blue line demonstrates the joint effects of the heredity factor, age and provoking factors (e.g. 
trauma, surgery or use of oral contraceptives) on the thrombosis potential at different time points. 
Provoking factors in early years of life may not be sufficient to reach the thrombosis threshold. 
However, a provoking factor later in life may contribute to exceed the thrombosis threshold (red line) 
and result in a VTE. If the thrombosis potential keeps on increasing following an incident VTE event, a 
provoking factor may exceed the thrombosis threshold again and result in a recurrent VTE.  
 
Classical environmental exposures (acquired risk factors) for VTE include advancing age, 
major surgery, trauma, hospitalization, obesity, prolonged immobilization, cancer, oral contraceptives, 
hormone replacement therapy, pregnancy, puerperium, acute medical conditions, and 
antiphospholipid antibodies (34, 46, 47).  
Advancing age is one of the strongest risk factors for VTE, and a number of studies support an 
association between increasing age and higher incidence of VTE (13, 16, 30, 48, 49). The incidence of 
VTE increases exponentially (14, 28) from 5 per 100 000 per year in individuals <15 years, to 
approximately 500 per 100 000 per year among individuals over 80 years (16). The risk increases 
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rapidly after the age of 45 years (13).  Studies have reported that age increases the risk of VTE nearly 
2-fold per decade (48) and the risk of VTE is 10 to 15-fold higher in individuals over 75 years as 
compared to those aged 45-54 years (50, 51). The reason for the increased risk of thrombosis with age 
is not fully investigated. However, it is suggested that it might be related to decreased mobility, 
degenerative vascular changes (46), more co-morbidities and increased plasma levels of haemostatic 
factors (fibrinogen, FVIII, FVII, d-dimer and homocysteine) or a combination of these (33, 52, 53). 
Although VTE occurs more frequently in older individuals (35), it can affect individuals of any age and 
sex (13). With increasing age in both males and females, PE accounts for an increasing proportion of 
the VTEs (13). The association between sex and risk of first time VTE has been assessed in many large 
cohort studies. Some studies reported higher risk of VTE in men than in women (13, 48), whereas 
others have shown a higher incidence of VTE in women than in men (24, 28, 54, 55). Moreover, in 
some other studies, the incidence of first VTE was approximately equal between the sexes (16). The 
variation in results of these studies could be explained by differences in the selection of the study 
population since the risk of VTE varies with age.  Women have slightly higher risk of VTE during 
childbearing age (16-44 years) compared with men of similar age,(13, 28, 56) whereas men have an 
overall higher risk of VTE after the age of 45 years (28, 29, 56). The Multiple Environmental and Genetic 
Assessment of Risk Factors for Venous Thrombosis (MEGA) study reported that the risk of a first VTE 
is 2-fold higher in men than in women once female reproductive risk factors (oral contraception use, 
post-menopausal hormone therapy, or pregnancy) for VTE are taken into consideration (57), 
suggesting that the risk of incident VTE is higher in men than in women. The pathophysiology behind 
these observations has not yet been disentangled.  
Recent major surgery is considered a strong risk factor for VTE (58). Surgical procedures 
associated with a high risk include neurosurgery, major orthopaedic surgery of the lower extremity, 
cancer surgeries of the thorax, abdomen or pelvis, and renal transplantation (59). Major surgery is 
associated with a 4 to 22-fold increased risk of VTE (58, 60). Several factors, such as advancing age, 
presence of comorbid conditions, endothelial damage and subsequent immobility after surgery, as 
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well as type and duration of surgery have been recognized as risk factors for VTE post operatively (61). 
Growing evidence also suggests increased TF expression and levels of procoagulant factors VII and 
fibrinogen on day 3 after major orthopaedic surgery of the lower extremity (62, 63). Additionally, minor 
surgical procedures, including central venous catheter and pacemaker insertion, have also been 
highlighted as risk factors for VTE (58, 64). 
Hospitalization is another risk factor for VTE. The average age- and sex-adjusted incidence of 
in-hospital VTE was 960 (95 % confidence interval [CI] 795-1125) per 10 000 person-years (PY) and 7.1 
(95% CI 6-7) per 10 000 PY among community residents (65). A population-based study reported that 
61% (95% CI 57-66%) of all confirmed cases of VTE could be attributed to institutionalization (current 
hospital or nursing home confinement) within the preceding 3 months (64). In a case control study, 
recent hospitalization with and without surgery was associated with a 22-fold and 8-fold increased risk 
of VTE respectively (58). Without prophylaxis, the estimated incidence of hospital-associated VTE in 
adult medical or general surgical patients ranges from 10% to 40% (66). Many of these events are not 
clinically evident, however, still could lead to life-threatening complications like PE. A study reported 
that approximately 10% of all deaths in hospitalized medical patients are linked to PE (67). Acute 
medical conditions, for instance, MI, stroke, infections, congestive heart failure and respiratory 
diseases are known to increase the risk of thrombus formation (3, 68, 69). Hospitalization for acute 
medical illness is associated with an 8-fold increased risk of VTE (70).  
Cancer is recognized as one of the most important risk factors for VTE. Almost 20% of all 
incident VTE events are associated with cancer (64, 71), and the overall risk of VTE is estimated to be 
4 to 7-fold higher in patients with cancer (58) compared with cancer-free individuals (23). The risk of 
VTE among cancer patients varies according to cancer type, stage and treatment options. The risk of 
VTE is high among cases with metastatic stage cancers particularly cancer of the brain, pancreas and 
stomach, whereas, prostate and breast cancer have generally been associated with a low VTE risk (72, 
73). In a population-based study, after adjusting for age, race, and cancer stage, VTE was associated 
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with a significant reduction in survival in cancer patients during the first year (range of hazard ratios 
[HR], 1.6-4.2; p <0.01) (72). Hospitalized patients with cancer had twice the incidence of DVT and PE 
as hospitalized patients without cancer (74). Risk of VTE is highly dependent on cancer-related (cancer 
type, stage, tumor grade, histological type, and time since cancer diagnosis), patient-related 
(advancing age, obesity, immobility, comorbid conditions, and inherited thrombophilias), and 
treatment-related (surgery, chemotherapy, radiotherapy, central venous catheters, erythropoiesis-
stimulating agents, and blood transfusions) risk factors (75). Several pathogenic mechanisms may 
promote thrombus formation in cancer patients including tumour induced platelet activation, 
enhanced expression of TF, reduced clearance of coagulation factors and decreased anticoagulant 
synthesis (63, 76). Moreover, it is likely that the tumour itself increases the risk of thrombosis by 
causing a procoagulant state through release of humoral factors (46).  
Patients with multiple trauma are also at high risk of developing VTE (77). In the absence of 
anticoagulant prophylaxis, thrombosis (symptomatic or asymptomatic) occurs in 50 % to 60 % patients 
with head trauma, spinal injury, pelvic, femoral, and tibial fractures (78). The magnitude of injury 
according to injury severity score, impact of operative interventions, presence of pelvic injury and 
spinal cord injuries are factors that places the individual patient at a higher risk of developing VTE (77).  
The rising prevalence of obesity, especially in the Western countries, is a growing public health 
concern. According to 2017 estimates from the World Health Organization (WHO), worldwide obesity 
rates have nearly tripled since 1975 (79). Growing evidence suggests that obesity (body mass index 
[BMI] over 30 kg/m2) is a risk factor for VTE (80). All measurements of obesity including BMI, body 
weight, waist circumference, hip circumference, and total body fat mass are associated with an 
increased risk of VTE (81-83). Elevated levels of FVIII, FIX, and plasminogen activator inhibitor-1 (PAI-
1) in obese individuals could likely contribute to the increased risk of VTE (7). Moreover, excess 
abdominal body fat may result in compromised venous return with subsequent venous stasis (80). 
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Venous stasis is an important risk factor for VTE and immobilization of the extremities, for 
instance due to paralysis, bed rest, plaster casts, and long-haul flights, increases the risk of thrombus 
formation (84, 85). In one study, immobilization (confinement to bed or armchair) was found to be 
associated with a 6-fold (95 % CI 2.3-13.7) increased risk of DVT (86). Moreover, in another study, 
asymptomatic DVT was found in 60% of paralysed limbs of stroke patients compared with 7% in the 
non-paralysed limbs (85). Prolonged immobility combined with other risk factors increases the 
probability of VTE (47). Without much difference for the various modes of travel, long haul flights (≥ 4 
hours) was associated with a 3-fold increased risk of thrombosis. The risk was mainly due to 
immobilization and reported to be higher for individuals with factor V Leiden (FVL), obesity and users 
of oral contraceptives (87).  
An association between pregnancy and VTE is well established and PE is reported to be the 
leading cause of maternal death in the developed world (88). Pregnant women have a 4 to 5-fold 
increased risk of VTE compared with non-pregnant women (89, 90). The steep incline in VTE risk during 
pregnancy may be explained by a large increase in levels of procoagulant factors (for instance, VII, VIII, 
X, fibrinogen, von Willebrand factor (vWF), and PAI-1 during normal pregnancy which returns to 
baseline levels after 8 weeks postpartum (91). Additionally, increased venous capacitance and reduced 
venous return in pregnant women along with mechanical obstruction by the uterus may contribute to 
pregnancy-related thrombosis (88). In the postpartum or puerperium period (6-weeks after delivery), 
the risk of VTE is 20 to 80-fold higher, probably due to endothelial damage to the pelvic vessels that 
occurs during labour (88, 89).  
Use of oral contraceptives is also an established risk factor for VTE in women and has been 
shown to increase the risk of VTE from 2 up to 7-fold especially during the first year of use depending 
on the dose of Ethinylestradiol and the type of progestogen (92). The third generation progestogens 
(desogestrel and gestodene) are associated with the highest risk of VTE (92). Increased levels of 
procoagulant factors (such as, VII, VIII, IX, X, XII, XIII, II, I), reduced concentration of the natural 
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anticoagulants (protein S and antithrombin), and an increased resistance to the anticoagulant action 
of activated protein C (APC) has been observed with oestrogen usage (93-95). Moreover, 
postmenopausal women taking hormone replacement therapy (with oestrogens) have a 2 to 3-fold 
increased risk of developing VTE (96).  
Individuals with antiphospholipid antibodies, both with and without underlying systemic 
lupus erythematosus (SLE) have an increased risk of VTE. Ginsberg et al. reported a strong association 
between lupus anticoagulant and VTE, with an odds ratio (OR) of 9.4 (97).  
In addition to acquired risk factors, a variety of inherited traits contribute to the overall risk of 
VTE in an individual. Family and twin studies have revealed that genetic factors account for 50-60% of 
the VTE risk (98, 99), and a family history of VTE is associated with a 2 to 3-fold higher risk of VTE (100). 
Inherited thrombophilias increase the risk of VTE predominantly by two mechanisms. The loss-of-
function of anticoagulant proteins (including deficiency of antithrombin, protein C, or protein S) or 
gain-of-function of procoagulant factors (such as factor V Leiden [FVL], prothrombin G20210A and non-
O blood group) (101, 102). 
Antithrombin is a glycoprotein produced by the liver and is a strong natural inhibitor of the 
coagulation cascade. Over 250 genetic mutations may result in Antithrombin deficiency (102). 
Antithrombin deficiency is a rare condition found in 1-2% of the VTE patients, and is associated with a 
10 to 50-fold increased risk of VTE (103). Protein C, encoded by the PROC gene, is a vitamin K-
dependent plasma glycoprotein that is synthesized in the liver and released into the bloodstream. 
Deficiency of protein C is a congenital or an acquired condition and leads to increased risk of 
thrombosis (104). Heterozygous protein C deficiency is present in 2-5% of VTE cases and <0.5% of the 
general population, and associated with a 10-fold increased risk of VTE (105). Protein S, encoded by 
the PROS1 gene, is a vitamin K-dependent single glycoprotein that is synthesized in the liver. Protein S 
functions as a cofactor to facilitate the action of activated protein C for the inactivation of activated 
factor V (FVa) and factor VIIIa. Deficiency of protein S is found in <0.5% of the general population and 
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in 2-12% of selected groups of thrombophilic patients (106), and family studies have suggested that 
the VTE risk is similar to that in patients with Protein C deficiency (104).  
FVL, prothrombin G20210A and non-O blood group are less thrombogenic, however, they are 
more common than the deficiencies of antithrombin, protein C, or protein S (104). Factor V (FV) is a 
single-chain glycoprotein encoded by the F5 gene. It is synthesized in the liver and circulates in the 
plasma as an inactive precursor. APC inactivates the activated form of FV. A polymorphism of FV (FVL 
mutation) is associated with APC resistance. As a result, FV protein retains its procoagulant role in the 
plasma (104). The overall prevalence of FVL mutation is about 5% among Caucasians in its 
heterozygous form (107). The FVL mutation yields a 2 to 3-fold increased risk of VTE (108). 
Prothrombin, encoded by the F2 gene, is a single-chain glycoprotein and one of the vitamin-K 
dependent factors synthesized in the liver. Prothrombin gene G20210A mutation causes the body to 
produce excess amount of prothrombin (109). The prevalence of this gene mutation is around 2% in 
the general population and carriers of this polymorphism have 3 to 4-fold increased risk of VTE (110). 
The occurrence of FVL and prothrombin G20210A varies with ethnicity and are more prevalent among 
white Europeans and Americans than among individuals of African or Asian descent (104). The ABO 
gene encodes proteins related to the blood group system that determines the blood group. The ABO 
phenotype correlates with plasma levels of FVIII and vWF (104). The non-O blood group phenotype 
confers a 1.5-fold increased risk of VTE (108) and to some extent, this association is due to increased 
levels of vWF and FVIII in individuals with non-O blood group (111). However, some studies have shown 
that non-O blood group remains significantly associated with VTE even after adjustment for FVIII or 
vWF levels (112), inferring a contribution of an unidentified pathway linking non-O blood group to the 
risk of VTE.  
Despite significant contribution of genetic factors influencing VTE risk, a review reported that 
common polymorphisms are expected to explain approximately 5-20% of VTE heritability (108). 
Genome-wide association studies (GWAS), performed during the last decades, have identified 12 novel 
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single nucleotide polymorphism (SNPs), which are associated with VTE and are frequent in the 
population. The OR associated with these risk alleles range from 1.15 to 1.50. These SNPs have a 
moderate influence on the risk of VTE and are therefore not likely to entirely explain the hereditary 
predisposition for VTE (108). Much remains to be done to disentangle the genetic variation of VTE. 
Therefore, it is expected that forthcoming whole-genome sequencing studies will identify novel 
genetic risk factors for VTE.  
 
1.4 Recurrence of venous thromboembolism 
1.4.1 Epidemiology of recurrent venous thromboembolism in the general 
population 
VTE is a chronic disease that frequently recurs (20, 39, 113). The risk of VTE recurrence after an incident 
VTE is highest during the initial 6 to 12 months, and then it declines with time (114) . The cumulative 
incidence of first overall VTE recurrence is reported to be 0.6-5% at 30 days, 7-10% at 6 months, 11-
18% after one year, 22.8% at five years, and 25-40% at 10 years (22, 23, 35, 48, 115-123). The variations 
in the reported cumulative incidence rates can potentially be explained by differences in study design, 
clinical setting, case definition, age restriction, and the time period in which the studies were 
conducted. In recent years, advances in diagnostics and management, out of hospital diagnosis, and 
treatment of VTE may have influenced the rates of adverse outcomes after VTE. For instance, the 
average length of hospital stay after a VTE has been reduced, and a large proportion of VTE cases are 
treated as outpatients (24, 39). Additionally, knowledge about VTE risk and the use of 
thromboprophylaxis in high-risk situations may also have affected the recurrence rates. Finally, the 
extensive use of high-resolution multidetector CTPA to diagnose PE, and the concomitant increased 
detection rate of subsegmental PE, may have influenced the overall outcome rates after a first VTE 
(38, 124).  
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Overall, few studies have assessed and compared the cumulative incidence of recurrence in 
the presence of competing risk by death in subcategories of patients with an incident VTE (125, 126). 
Additionally, other studies were conducted decades ago (22, 23), recruited patients after completion 
of anticoagulant treatment (3-12 months after the first event), and the study population was either 
outpatients or hospitalized patients (22, 121, 127). We therefore aimed to estimate the cumulative 
incidence of recurrence after a first VTE. With the purpose to assess the burden of VTE, we used cases 
derived from a general population cohort including both the hospital and community setting during 
1994-2012.  
 
1.4.2 Risk factors for recurrent venous thromboembolism 
The aetiology of the first VTE event is the primary driver of the risk of recurrence after discontinuing 
anticoagulants (128). If VTE occurs in the presence of provoking factors, the risk of recurrence is 
generally low and does not require prolonged treatment (> 3 months) with anticoagulants (3, 41, 129). 
For instance, in patients with VTE provoked by a major transient risk factor, the initial treatment can 
be limited to 3 months, as the annual risk of recurrence is only 1% after stopping anticoagulation (3). 
Patients with VTE provoked by a major persistent risk factor has a higher risk of VTE recurrence after 
discontinuing treatment than patients with VTE provoked by transient factors or unprovoked VTE (23, 
41, 130). Patients with unprovoked VTE have an intermediate to high risk of recurrence after 
discontinuing treatment (41, 129). Population-based studies have reported that 50-60% of the VTE 
events can be classified as provoked (28, 29, 123).  
Recurrences often occur at the same site as the initial event (DVT or PE). For instance, patients 
presenting with PE are three times more likely to suffer recurrence as PE than patients presenting with 
proximal DVT (131). Moreover, patients with DVT, in general, experience more recurrence than 
patients with PE. Studies have shown that patients with a first symptomatic DVT have a 1.5 to 2-fold 
higher risk of recurrence than patients with a first PE (115, 121, 132) .  
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Predictors of VTE recurrence include increasing age and BMI, male sex, neurologic disease with 
paresis, active cancer, inferior vena cava filter placement, and neurosurgery (23, 127, 133-135). 
Recurrent VTE occurs at a higher rate in men than in women, up to 10% per year versus 2-5% per year 
respectively (127, 136, 137). A meta-analysis reported that men have a 50% higher risk than women 
of recurrent VTE after stopping anticoagulant treatment (136). This meta-analysis included 11 cohort 
studies, five of these studies found an increased risk of recurrence in men [relative risk (RR) range= 
1.7-6.3], five studies found a weak or no association, whereas one study found a lower risk in men (RR= 
0.5). Previous studies have shown that recurrence risk is highest (>2-fold) when the first event was 
unprovoked (115, 138). In patients with a first unprovoked VTE, Baglin et al. reported a 2.5-fold higher 
risk of recurrent VTE in men compared with women at 2 years (134). Interestingly, men with a 
provoked first event still had a higher recurrence risk than women with an unprovoked first event 
(139).  
 
1.4.3 Hospital related venous thromboembolism and recurrence 
Hospitalization in itself is an interim exposure and may therefore be considered as a transient risk 
factor, presumed to be associated with a low risk of recurrence (23, 129). However, studies have 
reported that short-term hospitalization with (23) or without neurologic disease is associated with an 
increased risk of recurrence (125). There is not much data available on the risk of recurrence after 
incident hospital-related VTE, particularly hospitalization for conditions other than cancer or surgery. 
Therefore, it is necessary to investigate the risk of recurrence and mortality among patients with an 
incident VTE associated with previous hospitalization and to compare the impact of transient and 
persistent hospital-related factors such as surgery, cancer or other medical conditions (e.g. MI) on the 
risk of recurrence in models with and without death as a competing event.  
The most common statistical method employed to evaluate the recurrence risk of VTE has 
been the Kaplan-Meier (KM) approach, through which death is viewed as a censoring event (140-142). 
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The mortality rate is expected to be higher among patients with cancer and other comorbidities. The 
KM method, when used to estimate the cumulative incidence of recurrence of VTE, overestimates the 
cumulative incidence of recurrence due to failure to account for death as a competing risk. In our study, 
the cumulative incidence of recurrence may be influenced by the competing risk of death. Thus, 
application of the competing risk model, as suggested by Fine and Gray (143), may yield a more 
appropriate statistical estimate of the cumulative incidence of recurrence in patients with a hospital 
related first VTE.  
 
1.4.4 Myocardial infarction related venous thromboembolism and recurrence 
Arterial cardiovascular diseases (MI and ischemic stroke) are generally considered to be distinct from 
venous thromboembolic disease due to different pathophysiology, clinical presentation and treatment 
(144). In the past decade, however, this concept has been challenged (145, 146) when Prandoni et al. 
(145) found an association between subclinical atherosclerosis and VTE. Later, this finding has been 
refuted by others (147).  
Several epidemiological studies have shown that patients with incident VTE have an increased 
risk of subsequent arterial cardiovascular disease (CVD) (148-150). A large population-based Danish 
cohort study reported a 2-fold increased risk of subsequent arterial CVD in patients with VTE as 
compared with population controls (148). Growing evidence also supports an interrelation between 
CVD and subsequent VTE. Two large Danish population-based registry-studies have demonstrated that 
hospitalization for MI or stroke (151), or heart disease (152), was associated with an increased risk of 
VTE in the following 3 months after taking age, sex, obesity, medication use and comorbidities into 
consideration. Similarly, Rinde et al. showed that patients with MI had an increased risk of VTE, 
particularly during the first six months after the MI (68). Likewise, a meta-analysis showed that 4% of 
patients with MI experienced symptomatic PE within approximately 2 weeks after hospitalization 
(153). The potential mechanism behind the observed association between MI and the future risk of 
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VTE could include shared risk factors (obesity, smoking, and family history of MI), indirect factors 
(hospitalizations accompanied by episodes of immobilization following MI) or a direct causal 
relationship (sudden tissue damage associated prothrombotic response, disturbed cardiopulmonary 
circulation after MI, and heart failure related venous stasis). The transient increase in risk of VTE after 
MI reported in the population-based studies, suggests that MI is a transient risk factor for incident VTE 
(68, 152). This points towards transient mechanisms related to the MI itself (direct relationship), or 
indirect factors.   
If the relationship between MI and risk of VTE is purely transient, one would expect the 
recurrence risk of VTE to be low. It is, however, uncertain whether VTE patients with a history of MI 
are at increased risk of VTE recurrence. One study reported that presence of chronic cardiovascular 
disease in patients with symptomatic VTE was associated with a 2-fold increased risk of recurrent VTE 
during the initial 3 months of anticoagulant therapy (154). This points towards a persistent risk of VTE 
in patients with medical conditions such as MI. The risk of VTE recurrence in patients with a history of 
MI has not been extensively studied. We therefore aimed to investigate the association between 
history of MI and the risk of VTE recurrence in a cohort of patients with validated information on 
incident VTE and potential confounders.  
 
1.5 Mortality after venous thromboembolism  
1.5.1 Epidemiology of mortality after venous thromboembolism in the general 
population 
VTE is associated with substantial morbidity and mortality and is considered to be the leading 
preventable cause of in-hospital death (155). Extrapolated data from 6 European countries estimated 
that 370 012 VTE related deaths occurred in Europe in 2004, clearly indicating that VTE represents a 
major public health burden. Nearly three quarters of all VTE-related deaths were from hospital-
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acquired VTE (15). PE contributes to 5-10% of deaths in hospitalized patients (155). Moreover, 25% of 
all PE cases are thought to present as sudden death (156).  
A large study of 67 354 definite and 35 123 probable VTEs reported 30-day and 1-year case 
fatality rates of 10.6% and 23.0%, respectively (157). Rates of survival after a first VTE vary widely in 
previous studies, ranging from 77% to 97% at 1 week and from 61% to 75% at 8 years (22, 48, 115, 122, 
156). The short-term survival ranges from 95% to 97% (35, 48) in DVT patients, and from 77% to 94% 
in PE patients (35, 48, 119, 158), whereas long-term survival ranges from 61% to 75% for both DVT and 
PE (22, 35, 48, 118, 119). A study reported an overall 8-years cumulative incidence of mortality of 12% 
(159), whereas another study stated cumulative mortality rate of 52.5% at 8 years (156). The variation 
in the reported rates may partly be due to differences in study design (clinical trials (160, 161), cohorts 
or registry databases (162) with limited case validation), clinical setting (hospital (163, 164) or out-
patient setting (22, 122)), short follow up time (maximum 10 years (22, 35, 159, 165, 166)), the time 
period during which the study was conducted, age restriction (age <70 years (159) or 65-89 years (35)), 
and failure to examine mortality for DVT and PE separately (28, 159, 165). Advances in diagnostics, 
management and treatment of VTE may have influenced the rates of adverse outcomes after VTE. The 
length of hospital stay has been reduced since the introduction of LMWH for the treatment of VTE (24, 
39, 167-169). Increased awareness of VTE risk and the use of thromboprophylaxis in high-risk situations 
may also have impacted on mortality rates.  
Recent data regarding VTE mortality is limited and previous estimates vary considerably. From 
a public health perspective, it is important to determine the mortality rates of VTE during the last 




1.5.2 Predictors of survival after venous thromboembolism 
Patients diagnosed with VTE often have malignancy, heart disease or other comorbidities that are 
associated with increased risk of mortality (33, 170). In the absence of recurrent embolism, death 
usually results from these coexistent conditions rather than from fatal PE (156).  
 Predictors of reduced short-term survival include advancing age, male sex, low BMI, 
confinement to a hospital or nursing home at the onset of VTE, and a history of congestive heart failure 
(158), chronic lung disease (158), neurological disease, or cancer (156, 158, 170). A cohort study of 
patients in Olmsted County found that in multivariable adjusted analysis, among patients without 
cancer, the odds of death within 7 days after VTE for men were 44% higher than for women. A 
Norwegian study reported that the survival for patients with unprovoked VTE without cancer was 
higher than for patients with cancer-associated VTE (28). Confinement to a hospital or nursing home 
at the time of VTE onset was associated with poor survival across all ages (156).  
Predictors of reduced long-term survival include increasing age, event type, current or former 
smoking, confinement to a hospital or nursing home at the onset of VTE, and history of congestive 
heart failure, chronic lung and renal disease, neurological disease, or malignancy (156).  Heit et al. 
reported that long-term survival remained significantly reduced for patients with PE compared with 
DVT even after adjustment for comorbid conditions (156). Mortality data from the French 
Epidemiology Center on medical causes of death from 2000 to 2010 indicated that cancer, obesity, 
osteopathies, and surgical complications were more likely to be the underlying cause of death when 
PE was listed on the death certificate (171).   
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2. Aims of the study 
The aims of the study were: 
I. To describe the 16 years’ time trend (1996–2012) in the incident rates of VTE in a large 
population-based cohort, and to describe the prevalence of clinical risk factors and provoking 
factors of VTE at the time of VTE diagnosis. 
 
II. To estimate the cumulative incidence of recurrence and mortality after a first VTE by using 
cases derived from a general population cohort including both the hospital and outpatient 
setting, during the period 1994–2012. 
 
III. To investigate the risk of recurrence and mortality among patients with a first hospital-
related VTE, and to compare the impact of transient and persistent hospital-related factors 
such as surgery, cancer or other medical conditions on the risk of recurrence in models with 
and without death as a competing event. 
 
IV. To investigate whether a history of MI was associated with risk of VTE recurrence in a cohort 




3. Methods  
3.1 Study populations 
3.1.1 The Tromsø Study 
Paper I, II and III included in this thesis are based on Tromsø Study, whereas Paper IV also includes the 
Multiple Environmental and Genetic Assessment of Risk Factors for Venous Thrombosis (MEGA) follow 
up study.  
The Tromsø Study is a single center, population based cohort with repeated health surveys of 
the inhabitants of the municipality of Tromsø, Norway. The Tromsø Study is conducted by the 
Department of Community Medicine at the University of Tromsø. It was originally initiated in 1974 as 
the Tromsø Heart Study with a purpose to investigate and prevent arterial CVD, since cardiovascular 
mortality was high in North Norway during that time. The focus of the Tromsø Study has expanded 
over time, and at present, the Tromsø Study has become a large epidemiological study including a 
broad spectrum of diseases. So far, seven surveys have been conducted. The first survey was carried 
out in 1974, followed by surveys in 1979 to 1980, 1986-1987, 1994-1995, 2000-2001, 2007-2008, and 
most recently the seventh survey in 2015-2016. In all Tromsø surveys, baseline information was 
collected through self-administered questionnaires, non-fasting blood samples and physical 
examination performed by the trained personnel. 
Tromsø 1 was conducted in 1974 and men aged 20 to 49 were invited and 6 595 participated. 
The participation rate was 83%. Tromsø 2 invited men and women between 20 and 54 years and 16 621 
individuals participated (participation rate 74%). Tromsø 3 was conducted from 1986 to 1987 and 
21 826 individuals between 12 and 67 years participated, and the participation rate was 75%. Tromsø 
4 was conducted from 1994 to 1995, and a total of 27 158 individuals aged 25 to 97 years participated. 
Tromsø 4 is the largest survey of the Tromsø Study with a participation rate of 77%. Tromsø 5 was 
conducted from 2001 to 2002 and included 8 130 individuals (participation rate 79%) aged 30 to 89 
years. Tromsø 6 was conducted from 2007 to 2008 and included 12 984 individuals aged 30 to 87 years. 
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The participation rate was 66%. Tromsø 7 was conducted from 2015 to 2016 and included 21 083 
individuals aged 44 to 104 years (participation rate 65%).  
The VTE registry was started in 1994. In Paper I, participants from the fourth survey of the 
Tromsø Study were followed up from January 1, 1994 until December 31, 2012. In Paper II, participants 
from the fourth survey of the Tromsø Study who developed a first lifetime VTE were followed from the 
date of their VTE diagnosis until December 31, 2012 for VTE recurrence and all-cause mortality. In 
Paper III and IV, patients with a first VTE in the period 1994-2012, derived from the first six surveys of 
the Tromsø Study, were followed from the date of their first lifetime VTE diagnosis until the date of 
recurrence, date of death or emigration, or the end of the study period (Dec 31, 2012).  
 
3.2 Outcome measures 
3.2.1 Identification and validation of incident VTE events 
In the Tromsø Study, VTE events were recorded from January 1, 1994 up till December 31, 2012 (Paper 
I-IV). Three registries at the University Hospital of North Norway were used to identify VTE events 
during the follow-up: the hospital discharge diagnosis registry, the autopsy registry, and the 
radiological procedure registry. The University Hospital of North Norway is the only hospital in the 
region, and therefore, all outpatient and admitted patient medical care, relevant diagnostic radiology 
procedures and appropriate treatment of VTE in the Tromsø municipality is provided entirely by this 
hospital. Relevant International Classification of Diseases (ICD) 9th codes used in the search for cases 
were 325, 415.1, 451, 452, 453, 671.3, 671.4, 671.9 for the period 1994–1998, and the corresponding 
ICD-10 codes were I26, I67.6, I80, I81, I82, O22.3, O22.5, O87.1, and O87.3 for the period 1999–2012. 
Trained personnel, who were unaware of patients’ baseline variables, reviewed the medical journal 
for each potential VTE case. For subjects derived from the hospital discharge registry and the radiology 
procedure registry, an episode of VTE was verified and recorded as a validated outcome when all four 
of the following criteria were fulfilled; (1) signs and symptoms consistent with DVT or PE were present 
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(2) objective confirmation by diagnostic procedures (e.g. compression ultrasound of the whole leg, 
venography, CTPA, perfusion-ventilation scan [VQ-scan], or autopsy), (3) the patient’s medical records 
indicated a diagnosis of DVT or PE made by a physician, and (4) the patient received treatment for VTE 
(anticoagulant medication, thrombolysis, or vascular surgery) unless contraindications were specified. 
For subjects derived from the autopsy registry, a VTE event was recorded as an outcome when the 
autopsy record (death certificate) indicated VTE as cause of death or as a significant condition 
contributing to death. 
Verified VTE events were classified as DVT or a PE, and if DVT and PE occurred concurrently, 
the event was recorded as a PE. The events were further classified as cancer-related, unprovoked or 
provoked based on the presence of cancer or other provoking factors at the time of VTE diagnosis. The 
presence of cancer was defined as overt cancer at the time of VTE diagnosis (or, in some cases, if cancer 
was diagnosed on the same day as the VTE). VTEs occurring in patients with active cancer were 
classified as cancer-related regardless of other risk factors. A VTE occurring without any provoking 
factor was defined as unprovoked. In patients without cancer, a VTE event was defined as provoked if 
one or more of the following factors were present: recent hospitalization, surgery or trauma, (within 
eight weeks before the event), acute medical condition (acute MI, acute ischemic stroke, acute 
infections), immobilization (bed rest [3 days or confinement to wheelchair within the last 8 weeks, or 
long distance travel ≥4 hours within the last 14 days), or other factor specifically described as provoking 
by a physician in the medical record (e.g. intravascular catheter).  
 
3.2.2 Identification and validation of recurrent VTE events 
In the Tromsø Study, all VTE recurrences and deaths among the study participants were recorded 
during 1994 to 2012. Recurrent VTEs were identified and validated with the same approaches and 
criteria as used for first VTE described above. Information on deaths was collected from the Norwegian 
Population Registry by use of the unique national person identification number.  
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3.3 Myocardial infarction as exposure 
In Paper IV, we used MI as an exposure variable. In the Tromsø Study, all first-time events of MI were 
identified by searching the hospital and out of hospital medical records, the autopsy registry, and death 
certificates, as described previously (51). The national unique 11-digit identification number allowed 
linkage to national and local diagnosis registries and to the National Causes of Death Registry at 
Statistics Norway. This linkage allowed identification of fatal MI events that occurred as out-of-hospital 
deaths, including deaths that occurred outside Tromsø. The death certificate was used to gather 
relevant information on the MI events from additional sources, like autopsy reports, reports from 
nursing homes, ambulance services and general practitioners. Cases of incident MI were identified by 
linkage to the Discharge Diagnosis Registry at the University Hospital of North Norway with search for 
ICD 9 codes 410-414 during the years 1994 to 1998 and afterwards ICD 10 codes 120-125. The hospital 
medical records were case validated by an independent end-point committee. Slightly modified World 
Health Organization MONICA (Monitoring of Trends and Determinants in Cardiovascular 
Disease)/MORGAM (MONICA Risk, Genetics, Archiving and Monograph Project) criteria for MI were 
used; these included clinical symptoms and signs, findings in electrocardiograms (ECG), values of 
cardiac biomarkers, and autopsy reports when applicable. In our study, a history of MI was defined as 
an MI that occurred before the first VTE.  
 
3.4 Multiple Environmental and Genetic Assessment of Risk Factors for Venous 
Thrombosis (MEGA) follow-up study 
The aim of the MEGA follow-up study was to assess the incidence of recurrent VTE events and to 
identify novel risk factors and predictors of recurrence. The patients in the MEGA follow-up study were 
recruited from the population-based case-control MEGA study, the details of which have been 
described elsewhere (71, 172). Briefly, the MEGA study included 4 956 patients, aged 18 to 70 years, 
with a first objectively confirmed DVT of the leg, PE or both from 6 anticoagulation clinics in The 
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Netherlands, in the period between March 1, 1999 and August 31, 2004, (participation rate 86%). VTE 
events were classified as isolated DVT or an isolated PE, and if DVT and PE occurred concurrently, the 
event was recorded as both. Patients with an upper extremity venous thrombosis were excluded. Each 
potential VTE case was reviewed and validated by trained personnel by assessment of each patient’s 
medical record. Of the participants in the MEGA case-control study, only cases were further followed 
for recurrence (MEGA follow-up study). For this, 225 did not consent to participate. Thus, 4 731 
patients were eligible for the MEGA follow-up study, and these patients were followed from their first 
VTE. Between 2007 and 2009, the vital status of all MEGA follow-up patients were obtained from the 
Dutch Population Register. Causes of death were obtained from the National Registry of Death 
Certificates at the Central Bureau of Statistics and encoded according to the International Classification 
of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM).  Between June 2008 and July 2009, 
questionnaires concerning recurrent VTE were sent by mail to all survivors and consenting individuals, 
and supplemented by telephone interviews. Additional information on recurrences was acquired from 
the regional anticoagulation clinics and from hospitals. The end of follow-up was defined as the date 
of recurrence, date of death or migration, or the date of returning the follow-up questionnaire (the 
last questionnaire was returned on April 8, 2010). If patients did not respond to the questionnaire, 
they were censored from the last date the study investigators knew them to be recurrence-free (i.e., 
last visit to the anticoagulation clinic).  
In the MEGA follow-up study, potential cases of incident MI were identified by linkage to the 
Dutch Hospital Data Registry. For each hospital admission, information on the date of admission and 
discharge, diagnoses and surgical procedures was available. The diagnosis codes for MI were ICD-9-CM 
codes 410.0-410.9 and ICD-10-CM code I21. The percentage of correctly coded MI has been reported 
to be nearly 100% (173). In MEGA follow-up, a history of MI was defined as an MI that occurred before 
the first VTE.   
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4. Main results 
4.1 Paper I 
Time trends in incidence rates of venous thromboembolism in a large cohort recruited from the 
general population 
Alterations of risk factor levels, prevention strategies, diagnostic tools and treatment modalities over 
time may alter the rate of venous thromboembolism (VTE) in a community. Changes in the incidence 
of VTE during the last two decades have not been extensively studied. Therefore, we studied time 
trends in the incidence rates of DVT and PE in a large population-based cohort. A total of 26 855 
participants, aged 25-97 years, were enrolled in the Tromsø study between 1994 and 1995. The 
participants were followed-up to December 31st 2012. All symptomatic, objectively confirmed, incident 
VTEs were identified using multiple sources (hospital discharge diagnosis registry, radiology procedure 
registry and autopsy registry) and validated by review of medical records. Age-adjusted biennial 
incidence rates per 100 000 PY with 95% confidence intervals (CI) were calculated using Poisson 
regression. Between January 1, 1996 and December 31, 2012, 693 VTEs occurred during 368 150 PY of 
follow up. The incidence rate of VTE increased from 158 (95% CI 116–199) in 1996/1997 to 201 (95% 
CI 160–243) per 100 000 PY in 2010/2011. There was a marked increase in the rates of PE (with/without 
concurrent DVT) ranging from 45 (95% CI 23–67) in 1996/1997 to 113 (95% CI 82–144) in 2010/2011, 
whereas the rates of isolated DVT decreased (112, 95% CI 77–146 in 1996/1997 and 88, 95% CI 61–
115 in 2010/2011). Despite advances in prophylaxis, the incidence rate of VTE has increased slightly 
during the last 15 years, mainly due to an increase in PE. Although the introduction of better diagnostic 
tools to some extent may explain the increase in PE rates, our findings suggest that there is still a need 
for improvement in risk factor management and prevention strategies of first time VTE.  
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4.2 Paper II 
Recurrence and mortality after first venous thromboembolism in a large population-based cohort 
The recurrence and mortality rates after a first episode of VTE vary considerably in previous reports, 
and most of the studies were conducted several decades ago. Advances in the management and 
treatment of VTE during the last 15 years may have influenced the rates of clinical outcomes. 
Therefore, we aimed to estimate the rates of recurrence and mortality after a first VTE in patients 
recruited from a large population-based cohort. We used the Tromsø 4 Study which included 710 
patients with a first, symptomatic, objectively confirmed VTE followed between 1994 and 2012. 
Recurrent episodes of VTE were identified from multiple sources (hospital discharge diagnosis registry, 
radiology procedure registry and autopsy registry) and carefully validated by review of patients’ 
medical records. Information of deaths was obtained from the National Population Registry of Norway. 
Incidence rates and cumulative incidence rates with 95% CIs of VTE recurrence and mortality were 
calculated. The mean age of the patients was 68 years (range 28 to 102 years), and 166 (23.4%) had 
cancer at the time of first VTE. There were 114 VTE recurrences and 333 deaths during a median study 
period of 7.7 years (range 0.04 to 18.2 years). The risk of recurrence was highest during the first year. 
The overall 1-year recurrence rate was 7.8 (95% CI 5.8–10.6) per 100 PY, whereas the recurrence rate 
in the remaining follow-up period (1 to 18 years) was 3.0 (95% CI 2.4–3.8) per 100 PY. The risk of dying 
was highest in the first year following the VTE. The overall 1-year all-cause mortality rate was 29.9 
(95% CI 25.7–34.8) per 100 PY, and in those without cancer the corresponding rate was 23.6 (95% CI 
17.8–31.3) per 100 PY. Despite advances in VTE management, the rates of adverse events remained 




4.3 Paper III 
Hospital-related first venous thromboembolism and risk of recurrence 
Hospitalization is a well-established risk factor for first VTE, and previous studies suggest that 
hospitalization is one of the most important factors influencing the risk of VTE. However, the risk of 
recurrence, particularly in patients hospitalized for conditions other than cancer or surgery, has 
scarcely been investigated. The cumulative incidence of recurrence in hospital-related VTE may be 
influenced by the competing risk of death and may result in an over-estimation of the recurrence risk. 
Competing risk for death analysis should be taken into consideration when the rate of death differs 
greatly between two study groups. Therefore, we aimed to investigate the risk of recurrence and 
mortality among patients with a first hospital-related VTE in models with and without death as a 
competing event. Information on hospital-related risk factors was collected in 822 patients with a first-
lifetime VTE derived from the Tromsø study 1 to 6 surveys occurring in the period from 1994 to 2012. 
Recurrent VTEs and deaths were recorded in the follow-up period (1994 to 2012). During a median of 
2.79 years of follow-up, 132 patients experienced a recurrent VTE. Stratification on hospital-related 
factors revealed considerable differences in recurrence risk. The 5-year cumulative incidence of 
recurrence was 27.4%, 11.0% and 20.1% in patients with incident VTEs related to cancer, surgery or 
other medical illness, respectively, and 18.4% in patients with a non-hospital-related first VTE. The 
mortality rates were high for all subgroups of hospital-related VTE, except for surgery-related events. 
Consequently, the cumulative incidence of recurrence dropped in the competing risk analyses, 
showing a 5-year cumulative incidence of 14.4%, 11.7% and 9.7% in patients with a first VTE related to 
hospitalization for other medical illness, cancer or surgery, respectively. Our findings suggest that 
patients with incident VTEs related to hospitalization for medical illness other than cancer or surgery 




4.4 Paper IV 
Myocardial infarction is a risk factor for venous thromboembolism recurrence in women with a first 
VTE. 
Previous reports suggest that MI is a transient risk factor for VTE. Whether patients with a history of 
MI and VTE have an increased risk of VTE recurrence, remains unsettled. Therefore, we aimed to assess 
whether a history of MI was associated with risk of VTE recurrence in a cohort of patients with incident 
VTE. A total of 5494 VTE patients were recruited from the Tromsø Study and the MEGA follow-up study, 
and followed from the date of their first VTE until the date of recurrence, death, or emigration, or the 
end of the study period (Tromsø: Dec 31, 2012; MEGA: date of filling in the short questionnaire. The 
last questionnaire was returned on April 8, 2010). Cox regression models were used to calculate hazard 
ratios (HR) with 95% CI for VTE recurrence according to the history of MI adjusted for age, body mass 
index, cancer, and surgery. As a statistical interaction was found between history of MI and sex, and 
therefore, the analyses were further stratified by sex. During a median follow up of 11.2 years, 792 
patients experienced a recurrent VTE. In women, a history of MI was associated with 2.4-fold increased 
risk of VTE recurrence (HR 2.44; 95% CI 1.27-4.69). No association between a history of MI and VTE 
recurrence was observed in men (HR 1.17; 95% CI 0.70-1.94). In women with a history of MI, the 5-
year cumulative incidence of recurrence was similar to that in men both with and without a history of 






5. General discussion 
5.1 Methodological consideration  
5.1.1 Study design 
The first three papers in this thesis utilized data from the Tromsø Study, which is a large prospective 
population-based cohort. In paper IV, we additionally merged VTE patients from the first six surveys of 
the Tromsø Study with the MEGA follow-up study, yielding a cohort of VTE patients. The term “cohort” 
comes via the French word “cohorte” from the Latin word “cohors” in the 15th century.  A cohort was 
originally a standard military unit in the ancient Roman army, and 10 cohorts made up a Roman legion. 
Each cohort, comprising of 300 to 600 warriers, could be traceable during each battle. In the mid-20th 
century, its meaning was extended, to any group of individuals with something in common. In 
epidemiology, cohort means a group of people who share a common characteristic or experience 
within a defined period. In a cohort study design, a well-defined population is selected and the 
participants’ exposure status is recorded at study entry. Subsequent to this, the outcome of interest is 
investigated and compared in non-exposed and exposed individuals. In Papers I-IV, study participants 
were followed from the date of inclusion in the study until they were censored. Censoring is a process 
for dealing with follow up time when the event of interest (outcome) does not happen during the 
overall follow up period. Typically, this is due to death or migration or other reasons for loss to follow 
up, or may be because part of the sample survive the complete follow up time without experiencing 
the outcome (174). In our study, participants were censored by death, the end of the study period or, 
migration. In Paper I and II the source population was participants from Tromsø 4, whereas in Paper III 
and IV the source population comprised of individuals participating in one or more of the Tromsø 1-6 
surveys who were still alive and inhabitants of the municipality of Tromsø by January 1, 1994, since 
the VTE registry was started in 1994. Individuals with a known history of VTE at baseline were excluded 
from the analysis.  
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A cohort study is useful in estimating the absolute and relative risks of a disease. In Paper I, 
incident VTE events and in Paper II, III and IV, recurrent VTE events during the study period were 
registered and absolute risk estimates in terms of incidence rates and relative risk estimates in terms 
of hazard ratios were obtained, respectively.  
A cohort study has many advantages compared to other observational studies, such as case-
control studies and cross-sectional surveys. Cohort studies have a temporal sequence of exposure and 
outcome, which is one of the Bradford Hill criteria for establishing causality (175), and the outcome 
does not influence the exposure status since exposure(s) of interest is determined before the 
occurrence of outcome. The retrospective nature of case-control studies makes this design susceptible 
to temporal bias (reverse causality), as it cannot be established certainly whether the associated 
variable is a response to rather than a cause of the disease. Another advantage of cohort studies lies 
in large number of participants which may allow for generalizability of study results to other 
populations. Furthermore, cohort studies are non-experimental in nature, and therefore ethically safe. 
However, a cohort design is not the most efficient approach when the incidence of disease is low as it 
is both time consuming and requires a large number of individuals to be followed up for long periods 
before a sufficient number of cases occurs to generate statistically meaningful results. Case-control 
studies are therefore more appropriate for investigating rare diseases as case-control studies are both 
cost and resource effective.  
 
5.1.2 Bias 
Errors, particularly bias, is a principal interest in epidemiological studies and are the prime basis for 
incorrect results of epidemiologic investigations. Sources of error in measurements are classified as 
either systematic or random (176).  Systematic errors depend on any flaw that systematically leads to 
an over- or under-estimation of association between the exposure and the outcome, and this type of 
error is independent of sample size (176). For example, if the device we use to measure blood pressure 
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(sphygmomanometer), systematically over or underestimates the true blood pressure of the individual 
being evaluated. Rothman defines random error as “nothing more than variability in the data that 
cannot be readily explained” (176). It’s the error that remains after systematic error is eliminated. 
Random errors can be minimized by increasing the sample size. For example, if we measure serum 
creatinine level three times in the same individual using the same instrument and the same laboratory 
reagents, we are likely to obtain slightly different values due to clinical fluctuations in the serum 
creatinine level. Bias may threaten the internal and external validity of a study. The list of biases is a 
long one, however, Rothman classify bias into three broad categories: selection bias, information bias, 
and confounding (176).  
Selection bias (or Berksonian bias) arises when a systematic error occurs in the enrollment of 
individuals in a study, and results in a biased association between the exposure and the outcome. 
Selection bias is more likely to occur in case-control studies than in cohort studies, because, in cohort 
studies, both exposed and unexposed individuals are selected to the study before the occurrence of 
the outcome.  In contrast, both the exposure and outcome have occurred by the time the patient is 
recruited into a case-control study. In case-control studies, selection bias may occur when individuals 
selected as controls are not representative of the population that produced the cases. For example, in 
a hospital-based case-control study looking at the association between alcohol consumption and the 
development of liver cirrhosis, the association could potentially be underestimated if controls are 
taken from a trauma ward. This is because consumption of alcohol in large quantity may result in injury 
and consequently, an admission to the trauma ward. Self-selection is an issue that can threaten the 
external validity (generalizability) of a study. Self-section bias occurs when individuals select 
themselves into a group. For example, in the six Tromsø surveys, all, or parts, of the population living 
in the municipality of Tromsø were invited to participate. Although the attendance rates were high 
(177), invited individuals who did not attend the Tromsø Study tended to be younger (< 35 years), or 
older (> 80 years), were more often men and more likely to be single (177). A participation required 
physical attendance at the study site, and therefore, selection bias due to lower attendance rate in the 
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severely ill or disabled is likely to have occurred. VTE tend to occur more often in the elderly 
population, and under-representation of this part of the population may reduce the external validity 
of the results for this group. It is worth mentioning, however, that selection bias between health survey 
attendees and non-attendees is probably most theoretical. Since the attendance rate in Tromsø 
surveys was high, it is unlikely that this bias has a significant impact on our results. In Paper I, absolute 
risks (i.e. IRs) are predominately reported and we may perhaps expect a minor underestimation of our 
IRs for VTE in the elderly. However, in Papers II-IV, relative risks (i.e. HRs) are mainly reported, and 
thus, our results would not be largely affected. In general, non-respondents in population-based 
surveys tend to have low socioeconomic status and higher mortality than attendees (178).  However, 
it is not likely that the low participation rates and higher proportion of non-attendees with a low 
socioeconomic status has a large impact on the validity of the study results in this cohort, as the social 
class differences in Scandinavia are negligible compared to the rest of the world.  
 In epidemiological studies, information bias refers to bias arising from measurement error. 
This systematic error is also denoted as observational bias or misclassification. The term 
misclassification refers to an error in the classification of an exposure or the disease. For instance, 
misclassification occurs when an exposed individual is classified as unexposed or vice versa, or when a 
diseased individual is classified as non-diseased or vice versa. An example of misclassification is when 
normotensive individuals are categorized as hypertensive and vice versa due to the use of an 
inaccurate instrumentation (e.g. one size blood pressure cuff to take measurements on both lean and 
obese adults). Misclassification of individuals can be differential or non-differential (179). Differential 
misclassification bias refers to errors on one axis (exposure or disease) that are related to the other 
axis (exposure or disease). It can lead to either over- or under-estimation of the true association. Recall 
bias is a classic example of a differential exposure misclassification. Recall bias may occur when the 
recalled exposure differs between the cases and controls.  For instance, patients (cases) are much more 
prone to remember relevant exposures than healthy controls. Non-differential misclassification bias 
refers to errors on one axis that are unrelated to the other axis and such errors tend to be equally 
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distributed among cases and non-cases. This means that exposure is equally misclassified in cases and 
controls. For example, self-reported questionnaires is a possible source of misclassification, as items 
in the questionnaires may be misunderstood or the participants may over- or under-report their 
exposure level. For binary variables, non-differential misclassification tends to bias the association 
towards the null value (180). Cohort studies are more prone to non-differential misclassification, 
because exposure in a cohort study is usually measured before the onset of outcome (disease) of 
interest.   
In epidemiological and clinical studies, misclassification of both exposure and outcome is likely 
to occur. In all four papers in this thesis, the exposure and outcome variables were mainly extracted 
from the patients´ medical records by trained professionals or from validated registries (i.e. VTE and 
MI variables). Paper IV used information from the Tromsø Study and the MEGA follow-up study. In the 
Tromsø Study, the VTE and MI registries are separate, complete, and validated registries. In the Tromsø 
study, incident VTE events among study individuals were registered retrospectively at the end of 
follow-up by searching the hospital discharge diagnosis registry, the radiology procedure registry and 
the autopsy registry at the University Hospital of North Norway. This is the only hospital in the region 
to provide inpatient care and diagnostic procedures to the inhabitants of the municipality of Tromsø, 
and this increases confidence in thoroughness and completeness of the VTE Registry. We did a 
thorough search through all these registries to detect all cases treated at this hospital. However, some 
VTE cases could potentially have been missed due to diagnosis and treatment outside the region. With 
the purpose to make disease manifestation as certain as possible, the outcomes (incident VTEs in Paper 
I and VTE recurrences in Paper II, III and IV) were validated. We assured that the possibility of false 
positive VTE events was limited by following the strict validation criteria described in the methods 
section. For instance, by using these criteria, an asymptomatic venous thrombus that was identified by 
chance using computed tomography (CT) scan and remained untreated with anticoagulants would not 
be considered a clinical event.  
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 Retrospective registration is dependent on valid and complete information, and incomplete 
information from patients’ record could lead to inaccuracy. Therefore, regardless of using criteria for 
the validation of the outcome event, misclassification of VTE cases cannot be completely ruled out. 
Since the personnel who registered VTE events were blinded to the baseline information, any 
misclassification of VTE was most likely non-differential (called non-differential outcome 
misclassification). Thus, the misclassification was likely to be similar between the study individuals 
irrespective of whether they experienced the outcome. There were no standard instructions for 
reporting presence of clinical risk factors and provoking factors in the medical record and classification 
of an event as unprovoked or provoked relied on information provided by the individual physician who 
examined the VTE patient. In case information on the presence of a provoking factor (for example 
history of surgery during the last three months) was missing, a provoked VTE would be misclassified as 
unprovoked VTE. This could be a minor concern in Paper II and III where risk of recurrences were 
estimated according to the classification of the index VTE. 
Additionally, we did not have verified baseline information on previous history of VTE among 
the study individuals. Thus, some of the individuals who were treated as healthy during follow-up could 
be prevalent VTE cases who, ideally, should be excluded from the study population. For instance, in 
Paper I, the prevalent VTE cases may have contributed with person-years at risk while calculating the 
VTE incidence rates. However, as this concerns only a small fraction of the individuals, the effect on 
the incidence rates is most likely negligible.  
In the MEGA follow-up study, the VTE registration was validated as described in the method 
section. However, MI information was taken from the Dutch Hospital Data Registry because no 
separate MI registry exists. The percentage of correctly coded MI in the Dutch Hospital Data Registry 
has been found to be almost 100% (173). Participants of the MEGA follow-up study were linked to this 
registry through date of birth, sex and postal code. There could be some missing data regarding MI 
cases in the Dutch Hospital Data Registry and that may potentially be a source of misclassification. 
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Nevertheless, this potential misclassification of MI would most likely be non-differential since 
information regarding MI and incident VTE were collected prior to the outcome (VTE recurrence). Such 
misclassification may have caused underestimation of the true association between MI-related VTE 
and VTE recurrence in our study.   
 
5.1.3 Generalizability 
The validity of a study is usually separated into two components: internal and external validity. Internal 
validity refers to whether the inferences drawn are true to the members of the source population, 
whereas external validity is the degree to which the inferences drawn from a study can be applicable 
to a broader population beyond the study population (176). All types of studies in epidemiology raise 
concerns about extrapolation of study findings, which means “generalizability” from the study sample 
to the target population or to other populations or to the entire world.  
 High external validity means that the results of our study (Paper I to IV) can not only be 
generalized to the population of Tromsø but to the Norwegian and Scandinavian populations, and even 
to other Western populations. The VTE incidence found in our population (Paper I, II) is comparable to 
the incidence reported in other Western populations (28) (123). The Tromsø Study is a large 
population-based survey, reflecting the general population of the Tromsø municipality aged 25 years 
and above. The attendance rate range from 66% in Tromsø 6 to up to 83% in Tromsø 1 (177). The 
MEGA follow-up study also has a high attendance rate, as 79% of the invited population attended 
(181).  
 In the Tromsø Study, some groups of people are better represented than others. For example, 
in the Tromsø 4 survey, the participation rate was low for the youngest (< 35 years) and oldest (> 80 
years) population (58.5% and 46.3% respectively), and men had a lower participation rate than women 
(69.6% versus 74.9% respectively) (177). This threatens the generalizability towards these subgroups. 
As selection biases are one of the significant threats to external validity, the age-specific participation 
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rates and their effects on generalizability are mentioned in detail in the selection bias section. In the 
MEGA study, generalizability to elderly population (i.e. >70 years) could be an issue because patients 
were included in the study if they experienced their first event of VTE before they were 70 years old 
(182). Moreover, the majority of individuals in the Tromsø cohort and MEGA study were of Caucasian 
origin. Due to the limited ethnic diversity, the findings of our studies may not be representative of 
other ethnic groups.  
 As previously discussed, respondents in health surveys are generally considered to be more 
health conscious compared to the general population. Also, individuals who are ill or institutionalised 
are unlikely to attend health examinations. This bias between respondents and non-respondents may 
have affected our results; though only marginally, leading to an underestimation of the true incidence 
rates (IRs), as in Paper I, where absolute risks (e.g. IRs) are predominately reported.  
 
5.1.4 Missing data  
Missing observations is a common phenomenon in large cohorts. Missing observations could be due 
to multiple reasons, such as inadequate responses by the study participants to the questionnaires, 
participants being lost to follow-up, not all the selected individuals responding to a postal 
questionnaire survey, failure of the study equipment, or laboratory samples being lost or in a 
technically dissatisfactory condition (183). Missing data may affect the analysis. There are many ways 
of handling missing observations in the analysis. One approach is to omit variables with much missing 
information. An alternative is to omit study participants with incomplete data. Yet another option is to 
use imputation techniques (estimation) to replace missing values. Imputation refers to the 
replacement of a missing variable by an estimated value of that variable as derived from the available 
observed data.  
Missing data may introduce bias; though it largely depends on the reasons why data is missing. 
Missing data are generally classified as (i) missing completely at random, (ii) missing at random, and 
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(iii) missing not at random. Missing completely at random means no systematic differences between 
the missing values and the observed values. For example, blood pressure measurements may be 
missing due to the breakdown of the sphygmomanometer. Missing at random includes any systematic 
difference between the missing values and the observed values that can be explained by differences 
in the observed data. For example, if only males have missing values in a depression survey, the 
probability of missing data on depression will be related to sex. Missing not at random means that 
systematic differences remain between missing values and observed values even after the observed 
data are taken into account (184). A prerequisite for imputation is that the missing data is “missing at 
random”. If data is missing completely at random, analyses of only those with complete data will give 
valid inferences. Deletions may introduce bias if the number of excluded individuals is high and if the 
characteristics of those with missing values differ significantly from the ones included. Deletion may 
results in reduced statistical power.  
 
5.1.5 Statistical interaction 
The term statistical interaction applies to a situation in which the magnitude of the effect of an 
exposure differs depending on the level of a third variable. This variable is called “effect modifier” and 
this phenomenon is also known as effect modification (180).  Not like confounding, where the true 
association may be weakened or strengthened, interaction can result in variation in the risk estimates 
across strata of this third variable (180). The presence of statistical interaction is generally assessed in 
the regression analysis by entering a cross product term into the regression model. When an 
interaction is present, one common way of dealing with it is by stratifying the data on the effect 
modifying variable. 
In Paper IV, we assessed whether a history of MI was associated with risk of VTE recurrence in 
a cohort of patients with incident VTE. Epidemiological studies have shown that males have a higher 
VTE recurrence than females (127, 134). In addition, the incidence of MI is higher in males than in 
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females (185). We found a statistical interaction between MI-related VTE and sex i.e. the magnitude 
of the effect of exposure (MI before first lifetime VTE) on the outcome (VTE recurrence) varied 
according to the presence of a third variable (sex). Therefore, subsequent analyses were stratified on 
sex and the risk was increased in females but not in males. Stratification can sometimes be 
troublesome because increasing number of strata can limit the statistical power, since many of the 
strata may contain few people. This can lead to unreliable risk estimates. Lack of statistical power was 
a concern in Paper IV therefore, it was not possible to do further stratification.  
 
5.1.6 Confounding  
In epidemiology, a confounding factor (a third variable) is associated with the exposure and the 
outcome but is not an intermediate variable in the causal pathway between exposure and outcome 
(180). A variable laying on the causal pathway between exposure and outcome is called a “mediator”. 
Confounding if present, may weaken, strengthen or possibly change the direction of the association 
between the exposure and the outcome (180). Unlike experimental studies where the use of 
randomization reduces the likelihood of confounders, cohort studies have a potential issue of 
confounding. It is therefore necessary to adjust associations for possible confounders.  
In cohort studies, i) stratification, ii) multivariate analysis (modeling) and iii) standardisation 
(direct and indirect) are the analytical methods that are used to control for confounding effects (180). 
Stratification, includes dividing the study population into strata, or subgroups, based on the 
confounder and analyse the risk in these strata (180). Multivariable analysis is a statistical technique 
used to carry out adjustment where potential confounding variables are included as covariates in the 
regression model (180). In Paper II, III and IV, the Cox regression models were adjusted for sex and age 
at the time of incident VTE. In Paper II and III, while investigating the risk of VTE recurrence in patients 
with incident VTE, one concern was whether duration of anticoagulant treatment differed among 
comparison groups. Therefore, in addition to age and sex, we adjusted the Cox model for the planned 
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duration of anticoagulant treatment in Paper II. Likewise, in Paper III adjustment for planned duration 
for anticoagulant treatment was done when comparing hospital-related VTE and non-hospital-related 
VTE. In both conditions, the risk estimates (HR) were unchanged. Therefore, duration of 
anticoagulation was not a confounding variable in these groups of patients. While investigating all-
cause mortality in Paper II, we found a higher mortality rate in females than in males. This was due to 
a higher age of females at the index date, as the risk estimates changed after adjustment for age at 
incident VTE event. Therefore, age at the time of incident VTE event was a confounder for the 
association between sex and VTE-related mortality.  
Direct standardisation is used to control for confounding effects of age and sex in Paper I.  
Rothman defines standardisation as “a method of combining category-specific rates into a single 
summary value by taking a weighted average”. The weights used in averaging come from a standard 
population (176). In epidemiological studies, two methods of standardisation are commonly used. In 
the direct standardisation method, a common age-structured population is used as a standard, 
whereas in the indirect standardisation method a common set of age-specific rates is applied to the 
populations whose rates are to be standardized. In Paper I, we described 16-years’ time trends in 
incidence rates of VTE in a large cohort. We calculated overall crude incidence rates of VTE and 
expressed as number of events per 100 000 PY. We have used both direct and indirect standardisation 
in our study. For the purpose of comparison, we used the direct standardisation method and calculated 
the overall incidence rate of VTE standardised towards the “World Health Organization (WHO) 
standard population 2000-2025” (186). Age standardized rates account for the differences in the age 
structure of the populations being compared (180). Since Tromsø 4 is a closed cohort, the age 
distribution of the individuals would change over time. To be able to compare the rates over time, we 
therefore calculated age-adjusted biennial incidence rates of VTE, DVT and PE for the periods 1996/97, 
1998/99, 2000/01, 2002/03, 2004/05, 2006/07, 2008/09 and 2010/11 using Poisson regression. With 
the purpose to investigate whether the change in the incidence of PE and DVT could be attributed to 
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certain age group, we compared the age-specific incidence rates in the first half period (i.e. 1996-2003) 
with the second half period (i.e. 2004-2012).  
In Paper II and III, we used age as a time-scale. Typically in cohort studies, the time-scale used 
in the Cox regression model is time-on-study, and age is added as a covariate to the model for the 
purpose of adjustment. In the time-on-study scale, individuals start follow-up at the calendar time 
(date) they are included into a study and are followed-up until the date they are censored (experience 
the outcome, drop out or end of follow-up). When age is used as a time-scale, follow-up begins at the 
age a person is at study inclusion, and his/her age at censoring (occurrence of outcome or end of 
follow-up) is the exit-time. The risk of VTE is more dependent on age than the time the person has 
been in the study. Accordingly, using age as the time-scale, the risk of VTE in study individuals is 
compared in people of the same age, instead of in people with the same duration of follow-up (187). 
Therefore, it is more reasonable to use age as a time scale than time-on study as time scale. Age as the 
time scale approach is considered appropriate in longitudinal studies with a large sample size, since 
many people are represented in each age group. 
Even after using various methods to control for confounding in our analyses, the possibility of 
residual confounding cannot be ruled out. “Residual confounding is a term for confounding that 
remains even after many confounding variables have been controlled” (179).  Residual confounding 
can occur if data regarding confounders is not collected, if there are differences in risk within a 
confounder category, or if confounder misclassification is present (179). 
 
5.1.7 Competing risk of death 
The concept of censoring is a characteristic feature of survival analysis. In prospective studies, if an 
individual is lost to follow-up (for instance due to migration) that individual is treated as censored 
because whether that person experienced outcome of interest or not, remains unknown. Death is 
often handled as a censoring event in prospective studies, and death from any cause may prevent the 
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outcome from occurring. An assumption of censored survival time is that censoring should be non-
informative. This means that at any given point in time, individuals who remain in the study have the 
same future risk of developing the outcome as those who are no longer under follow-up. In Paper II, 
patients with cancer-related VTE had higher mortality rates than those without cancer (provoked and 
unprovoked) and therefore, censoring occurred differently in these exposure categories. Similarly, the 
mortality rate was expected to be higher among patients with co-morbid conditions (in Paper III).  
Competing risk regression is the most commonly used statistical technique when occurrence 
of one event is likely to alter the chance of another event (143). Cancer (in Paper II) and other 
comorbidities (in Paper III) are associated with increased mortality and hence death may have 
interfered with the outcome of interest (VTE recurrence). In routinely used traditional time-to-event 
analysis methods such as the Kaplan-Meier estimator (1-KM), the log-rank test (LRT) or the Cox 
proportional hazards model, when a death occurs, the probability of a subsequent VTE drops to zero. 
To address this issue, Fine and Gray introduced a statistical model which can account for competing 
events, like death (143). The competing risk of death methods do not censor patients on the date of 
death. Therefore, the probability of experiencing the outcome of interest is presented irrespective of 
competing mortality. This theoretically leads to unbiased and perhaps more meaningful results (141).  
Ay et al. compared competing risk of death analysis with traditional time-to-event approaches 
(1-KM, LRT and Cox regression) on the risk of VTE in a cohort of cancer patients (140). They concluded 
that traditional methods (1-KM and Cox regression) provided biased estimates of VTE risk, inferring 
that risk of VTE was over-estimated when compared with competing risk regression (140, 188). The 
authors suggested that competing risk of death analysis should be considered in populations at high 
risk of death, randomized trials with interventions that have a differential effect on death rates, non-
randomized trials with diverse death rates between groups, and in risk score developmental studies 
(prognostic studies) that may potentially have an impact on medical decision making (140).  
Conversely, traditional analysis methods are suitable for studies dealing with etiological questions.  
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Competing risk of death analysis was performed in Paper II and III. The risk of VTE recurrence 
was compared in cancer-related, provoked and unprovoked VTE (Paper II), and in hospital-related and 
non-hospital-related VTE (Paper III). As expected, the risk estimates were over-estimated using Cox 
regression when compared with competing risk regression in Papers II and III. In Paper II, when 
evaluating the risk of VTE recurrence in patients with cancer-related VTE compared to patients with 
provoked and unprovoked VTE, there was a difference in the risk estimates between the traditional 
method (1-KM) and the competing risk of death regression approach. The 5-year cumulative incidence 
rates for cancer-related VTE using 1-KM and competing risk regression were 26.4% and 11.4% 
respectively. This difference in the risk estimates between the traditional method and competing risk 
of death regression approach is driven by the differences in mortality among cancer and non-cancer 
patients. Accordingly, the cumulative incidence of VTE recurrence did not differ greatly between 1-KM 
method and competing risk regression in provoked VTE (16.7% versus 14.4%) and unprovoked VTE 
(17.9% versus 16.1%). This is as expected as the mortality rates did not differ much in unprovoked and 




5.2 Discussion of main results 
5.2.1 Venous thromboembolism: incidence, recurrence, and mortality  
In Paper I, we described trends in the incidence of VTE in a large population-based cohort from 1996 
to 2012. Within a well-defined geographical area (i.e. the Tromsø municipality) we observed a 27% 
increase in the overall age-adjusted incidence of VTE throughout the study period, from 158 to 201 
per 100 000 PY in the period 1996/97- 2010/11.  The observed incremental trend was largely due to 
an increase in the rate of PE throughout the study period. The age-adjusted IRs of PE increased by 
151% from 45 to 113 per 100 000 PY, while the rates of DVT decreased by 21% from 112 to 88 per 
100 000 PY during the study period. Our results indicate that despite advances in thromboprophylaxis, 
the annual incidence rates of VTE have increased during the last couple of decades. Hence, VTE remains 
a growing public health challenge.  
Studies from other countries have reported similar results (39, 113). In agreement with our 
findings, the Worcester VTE Study, which included 3887 incident VTE cases, reported an increase in 
the age- and-sex-adjusted incidence rates of VTE by nearly 40% from 95 to 133 per 100 000 PY in the 
period 1999-2009. The rate of PE increased by 116% from 30 to 65 per 100 000 PY, whereas the rates 
of isolated DVT remained almost constant in the same period (39). Additionally, a study based on 
Medicare and commercial insurance databases reported that the U.S. prevalence of VTE increased by 
33% from 317 to 422 per 100 000 PY in the period 2002-2006 (113). Contrary to our findings, Delluc et 
al. reported that the standardised overall annual incidence of VTE was reduced by 28% between 1998 
and 2013, and this reduction was mainly driven by reduction in the incidence of DVT of 47%, whereas 
the standardized annual incidence of isolated PE significantly increased by 29% within the same period 
of time (37).  
How might the observed increase in VTE incidence in our study be explained? The reason for 
the increase in the IRs of VTE during the study period is likely to be multifactorial. Predominately, the 
use of one or more noninvasive diagnostic methods for the detection of VTE increased approximately 
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three times during the study period. The proportion of patients with PE who underwent a high-
resolution multi-detector CTPA diagnostic test increased from approximately 23.1% in 1998/1999 to 
76.0% in 2010/2011. Thus, the increasing age-adjusted incidence of PE corresponds well with the 
increased use of CTPA at our hospital from year 2000 and onwards, showing that we are detecting 
more PEs than before the introduction of newer technology. In a randomized controlled trial that 
compared CT scan with VQ scan for the management of patients with suspected PE, CT scan strategy 
resulted in a significant 30% increase in the number of PE diagnoses as compared with VQ scanning 
(189). In accordance with our findings, Wiener et al. (38) conducted a time trend analysis using the 
Nationwide In-patient Sample with Multiple Cause-of-Death databases, and demonstrated that the 
introduction of multi-detector CTPA was associated with an increasing frequency of PE in the U.S. In 
an Australian study, Segard et al. (190) found an increase in PE-related imaging from 2002-2010, which 
was exclusively driven by increased referrals for CTPA, resulting in more PE diagnoses, while the total 
number of deaths from PE in the population remained unchanged.  
A challenging question is whether minor (subsegmental) PEs are of clinical significance? 
Indeed, the comparatively consistent mortality rate from PE during the last decades, combined with 
improved case fatality rates point towards overdiagnosis of PE (38, 190, 191). A systematic review and 
meta-analysis confirmed that many of the additional emboli identified by CTPA were subsegmental 
emboli that did not lead to adverse outcomes even if left untreated (124). Similar findings were 
observed in New York State’s (NYS) Statewide Planning and Research Cooperative System (SPARCE) 
database (169). The SPARCE study suggested that the diagnosis of PE in NYS approximately doubled 
during 1994-2004, while deaths and hospital admissions in patients with PE remained relatively stable. 
If we take a closer look at our data, the age-adjusted IRs of PE increased by 84.4% during 1996-2005, 
but were almost constant during 2006-2011. This may indicate that with a wide use of multi-detector 
CTPA we had reached the maximum detection rate of PE after 2005. 
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The apparent decline in DVT incidence during our study was most probably explained by the 
way PE was recorded (i.e. PE with or without coexisting clinical DVT). Detection of more PEs in patients 
with coexisting symptomatic DVT would consequently result in more events coded as PE rather than 
DVT. When the second half of the study period (2004-2012) was compared to the first half (1996-
2003), the rates of PE appeared to be predominantly increased among those >70 years. The potential 
explanation could be a lower threshold to perform diagnostic procedures for the detection of PE in the 
elderly after the introduction of CTPA.  
In addition to changes in the diagnostic assessment of VTE, an increase in the IR of VTE 
observed in our cohort could be related to changes in population characteristics over time. In general, 
the prevalence of major VTE risk factors such as ageing, obesity and cancer are increasing in Western 
populations (192). Despite more focus on the use of thromboprophylaxis during the last decades, the 
incidence of provoked VTE in our study did not decrease over time. This implies that there is still room 
for improvement in VTE prevention strategies.   
In contrast to our findings, Delluc et al. (37) reported a decrease in the incidence of VTE in 2013 
compared to 1998. It is worth mentioning that this study included both incident and prevalent VTE 
cases while calculating IRs. Additionally, the study was revolved around two cross-sectional 
measurements of all symptomatic VTE cases in 1998 and 2013. The IRs could be vulnerable to random 
fluctuations, and two separate measurements does not necessarily reflect a time-trend. The authors 
stated that the decrease in the VTE rates observed in their study could be related to a more widespread 
implementation of thromboprophylaxis in hospitalised patients.   
 After a first event, VTE has a strong tendency to recur (193). Advances in diagnostic procedures 
and medical management of VTE during the last decade may have influenced the outcome rates after 
a first VTE. In Paper II, incidence rates and cumulative incidence (also called cumulative proportion, 
risk) of recurrence and all-cause mortality after a first event of VTE were assessed. Our study extracted 
data during 1994-2012 from both hospital and community settings and the follow-up period started 
57 
 
immediately from the date of first VTE. Our cohort had a median follow-up of 2.7 years (range 1 day 
to 18.1 years) for recurrence and 3.4 years (range 1 day to 18 years) for mortality. This allowed us to 
describe the clinical epidemiology of VTE and subsequent outcome (recurrence and mortality) in detail.  
The overall incidence rate of recurrent VTE per 100 PY was 3.9 but varied substantially over 
time with a peak at 9.2 in the first 6 months, falling to 6.3 at 6 months-1 year, and 2.3 at 5-10 years. 
The cumulative incidences were 4.3% at 6 months, 7.3% at 1 year, 18.8% at 5 years, and 28.3% at 10 
years. Our recurrence rates were lower than those described in studies using a cohort derived from 
the United Kingdom Clinical Practice Research Datalink, which assessed the rates of recurrent VTE in 
patients with (114) and without cancer (194) during 2001-2012. Cohen et al. (114)  reported an overall 
incidence rate of recurrent VTE per 100 PY of 9.6; 22.1 in first 6 months, and 7.9 at 6 months- 1 year. 
In the same study, the cumulative frequencies of recurrence at 6 months and 1 year were 7.4% and 
9.2% respectively. The Worcester VTE study (166), conducted during 1999-2003, reported a 1-year 
cumulative incidence of recurrence of 10.7%, but did not assess long-term follow up. Heit et al. (23) 
investigated recurrence among 1719 patients with a first VTE in the period 1960-1999, and reported 
an overall cumulative incidence of recurrence of 10.1% at 6 months, 12.9% at 1 year, 22.0% at 5 years, 
and 30.4% at 10 years. Compared to the previous studies, our rates were lower in the initial year after 
the VTE, whereas the long-term rates were similar. At our hospital, all distal DVTs are treated with oral 
anticoagulants, and patients are often treated for 6-12 months. Nearly 65% of the VTE patients in our 
study were treated with anticoagulants for more than 3 months. Thus, extended duration of treatment 
in our hospital may to some extent explain the moderately lower 1-year recurrence risk compared to 
the other studies. The consistent long-term recurrence risk supported a catch-up, or rebound, effect 
after the initial treatment period.  
In our study, the recurrence rates in all subgroups were highest during the first 6 months after 
the VTE despite the use of anticoagulant therapy during this period. This indicates the importance of 
recruiting patients at the time of event, especially for descriptive epidemiological purposes, because 
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studies may lose a significant number of cases that occur in the initial phase if follow-up is started after 
the withdrawal of anticoagulants (127).   
In accordance with previous studies (125, 126), we found highest cumulative risk of recurrence 
among cancer patients. The mortality rate in patients with cancer-related VTE is high (114). 
Accordingly, when competing risk of death was taken into account, the cumulative risk of VTE 
recurrence in our study (Cox regression versus competing risk of death) was markedly lower (16.3% vs. 
4.9% in the first year and 26.4% vs. 11.4% at 5 years). Moreover, the cumulative incidence of 
recurrence was lower in cancer-related VTE that in non-cancer related VTE when competing risk was 
taken into account. In contrast to our findings, Heit et al. (125) reported a higher 5-year cumulative 
incidence of recurrence in cancer-related VTE when compared with non-cancer-related VTE (34% 
versus 17%) even after taking competing risk into account. The difference in the results may partly be 
explained by differences in mortality rates between the studies, especially among cancer patients, the 
definition of active cancer, and the length of follow up. In unprovoked VTE cases, we found that the 
recurrence risk in the first 10 years of observation remained high even after competing risk of death 
regression (30.3% versus 21.7%) as compared to cancer-related (26.3% versus 15.6%) and provoked 
VTE cases (25.8% versus 19.6%).  
In our study, recurrence throughout the 10 years period was influenced by whether the index 
event was a DVT or PE. The recurrence risk was higher in patients who initially presented with DVT 
than in those who presented with PE (HR 1.45, 95% CI 0.96-2.18). In a Canadian study of 646 patients 
with a first symptomatic unprovoked VTE (132), patients with DVT as their index event had a 2-fold [RR 
2.1 (95% CI 1.2-3.7)] higher risk of VTE recurrence than patients with PE as their index event.  Similarly, 
Prandoni et al. (115) found that patients presenting with primary DVT were 1.4-fold (HR 1.44 95% CI 
1.03-2.03) more likely to develop recurrence than patients with PE. A potential explanation for this 
phenomenon could be the higher fibrinolytic activity in the lungs (195), i.e. that the clot resolution in 
the lung may be more efficient than in the venous valve. Moreover, impaired coagulation inhibition 
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could be another reason of DVT recurrence in patients with DVT at first place. Development of post-
thrombotic syndrome also predisposes recurrences in DVT (22). Additionally, the introduction of multi-
detector CTPA to diagnose PE may have led to increased detection of subsegmental PEs, which have a 
better prognosis regarding recurrence (38, 196).  
The mode of presentation of the first VTE event (DVT or PE) predicts the type of recurrence 
(131). In accordance with previous studies (131, 193, 197-199), patients with a first PE had a 2.4-fold 
higher risk of experiencing second PE rather than a DVT in our study. Additionally, our findings showed 
that those with a first unprovoked VTE were more likely to have a second unprovoked VTE. This finding 
is in line with a cohort of patients with a first unprovoked VTE (200), where 90% of the recurrences 
were unprovoked. In our study, those with a first provoked VTE were at equal likelihood of 
experiencing provoked or unprovoked VTE as their second event. This could potentially be explained 
by residual vein thrombosis (201, 202) or other pathophysiologic alterations in the veins due to the 
first VTE that may enhance the risk of recurrence even in the absence of provoking factors.  
Risk of recurrent VTE is strongly predicted by the sex of the patient (193). Like other studies 
(127, 136, 198, 203), our study showed that the overall recurrence risk was higher in men than in 
women. Most previous studies reported a 2- to 4-fold increased recurrence risk among men (127, 203). 
The 10-years cumulative risk of recurrence in our study was 35.4% in men and 22.0% in women. 
However, the relative risk of recurrence was only 30% higher in men than in women, and the difference 
was not statistically significant. In our study population, the VTE cases were limited to patients of ≥ 25 
years, and our data did not contain very young women with a first VTE related to oral contraceptives 
or pregnancy. In general, young women with hormone-related VTE have a lower risk of recurrence 
(193, 204), and consequently, the risk difference between men and women will be higher in such VTE 
population that contains these women. Furthermore, in our study, the cumulative incidence curves for 
VTE recurrence in men and women started to deviate three years after the initial event. This may to 
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some extent explain the higher relative risk differences in men versus women observed in studies with 
a later start of follow-up (after withdrawal of anticoagulants).  
In a Norwegian study, Næss et al. (28) included 740 incident VTE cases during 1995-2001. The 
1-year case-fatality rate was 21.6% in all VTE cases and 63.4% in VTE cases with cancer. In our study, 
the 1-year mortality rate after VTE remained high and was remarkably similar to that reported by Næss 
et al. (28).  We found a lower survival among patients with provoked VTE than those with unprovoked 
VTE during the study period. This was probably explained by concurrent comorbid conditions and 
advancing age among patients with provoked VTE. We observed better survival rates among men in 
our crude analyses. This was, however, explained by the age differences among men and women at 
the time of first VTE.  
Papers I and II confirm that the disease burden of VTE remains substantial. With high long-
term morbidity, functional disability, and high rates of recurrence and mortality, VTE (205) remains a 
major health concern (15, 39, 206). Despite advances in thromboprophylaxis in the recent years, the 
annual event rate of VTE has increased over time (20, 39, 113). While this increase may partially be 
explained by improved sensitivity of diagnostic methods, it may also imply that current prevention and 
treatment strategies are not sufficient. Given the considerable economic burden of VTE (192, 207), 
imposed by the management of acute events and costs associated with long-term complications, 
further research is therefore needed to identify novel risk factors in the population in order to improve 
risk stratification, prevention, and management of VTE. Moreover, public health initiatives are greatly 
needed to increase awareness of symptoms and risk factors of VTE in the population. Treatment with 
anticoagulants is effective in preventing VTE recurrence (208) and a minimum of 3 months of 
anticoagulant treatment is recommended in all patients with VTE (3).  Our study showed that the risk 
of adverse events remained high and continued for at least 10 years and even longer after the incident 
event. With a purpose to reduce the global burden of VTE, and hence improve patients’ survival, future 
studies should focus on the development of risk prediction models with a purpose to stratify 
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individuals who are at high risk of developing a VTE with a favourable balance of risks and benefits of 
anticoagulation treatment.   
 
5.2.2 Hospital-related and myocardial infarction-related first venous 
thromboembolism and risk of recurrence  
In Paper III, we investigated the risk of recurrence and mortality among patients with first hospital-
related VTE in models with and without death as a competing event. Studies have reported that the 
risk of recurrent VTE is generally low for transient risk factors (23, 129, 209) because the effect of the 
risk factor is reversible. Therefore, the momentary nature of hospitalisation could imply a low 
recurrence risk, and if this notion holds true, then there should be a low risk of recurrence among those 
with a first hospital-related VTE. However, in our study, hospitalisation (within 8 weeks preceding an 
incident VTE as well as patients admitted at the time of event) was not associated with a lower risk of 
recurrence. A hospital-related VTE per se was not associated with an increased risk of recurrent 
thrombosis in the age and sex adjusted model (HR 0.99). However, the reason for hospitalisation 
preceding the first event appeared to have a great influence on the risk of recurrence. 
In the traditional Cox regression model, we found that the cumulative risk of VTE recurrence 
at 5 years was highest in patients with incident VTEs related to cancer (27.4%) followed by patients 
who were hospitalised for other medical illness within 8-weeks before first VTE (20.1%), and those with 
non-hospital-related VTE (18.4%). The lowest risk of recurrence was observed in patients who 
developed a first VTE after surgery (11.0%). Previous studies have also shown that patients with 
surgery-related first VTE have a low risk of recurrence (23, 121, 129, 130, 138, 154, 193, 209) whereas 
cancer, which is a persistent and often an irreversible risk factor, is associated with a high risk of 
recurrence (23, 121, 130, 154).  
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In our study, a hospital-related first VTE was associated with a 3-fold higher risk of death 
compared with non-hospital-related VTE. Moreover, compared with non-hospital-related VTE, the risk 
of death was 7.4-fold and 2.2-fold among patients with a first VTE related to hospitalisation for cancer 
or other medical illness, respectively. In accordance, previous studies (156, 198, 210-212) have shown 
that acute medical conditions such as cardiac, neurological, pulmonary, hepatic, and renal diseases are 
associated with 2-fold to 4-fold increased risk of death in patients with VTE. We found that patients 
who developed VTE within 8-weeks after surgery had a 13% lower risk of mortality compared with 
non-hospital-related VTE, which is in agreement with results of previous studies (22, 156, 159, 213). 
When competing risk of death was taken into account, we found that the 5-year recurrence risk was 
markedly lowered for cancer (11.7%), and those hospitalised for other medical illness had the highest 
cumulative incidence (14.4%). This indicated a considerable role of hospital-related mortality in 
estimating recurrence risk among these patients.  
The high risk of recurrence after a first VTE related to hospitalisation for medical illness points 
towards a persistent nature of the VTE risk in these subjects. Various chronic conditions, such as 
chronic heart and lung disease, and inflammatory or autoimmune disorders, are associated with 
coagulation and fibrinolytic abnormalities (214), endothelial dysfunction (214), platelet activation 
(215), and inflammation (214, 215), which may contribute to a prothrombotic state. Additionally, 
disease-specific mechanisms, such as hypoxia in patients with chronic obstructive pulmonary disease 
(COPD) (215), and right ventricular failure with subsequent venous stasis in patients with congestive 
heart failure (216) may contribute to VTE risk and lead to re-hospitalisation. This notion is supported 
by Heit et al. (125) who reported an almost 6-fold increased risk of VTE recurrence during hospital stay 
among patients hospitalised for medical illness.  
Improved stratification for risk of recurrence after a first VTE is important because it has 
implications on the duration of anticoagulant treatment (125). This is a complex decision because it 
requires assessment of an individual patient’s risk of developing unprovoked recurrent VTE and 
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anticoagulant-related major bleeding (125, 208, 217). For patients with a VTE provoked by a non-
surgical transient risk factor, current guidelines recommend 3 months anticoagulant treatment over 
long-term therapy (3). Though hospital admission for a medical condition, besides cancer or surgery, 
is a transient condition, a high VTE recurrence risk among these patients suggests a persistent 
underlying VTE risk, which may justify similar treatment recommendations as for those with 
unprovoked VTE.   
In Paper IV, we reported that a history of MI was associated with an increased risk of VTE 
recurrence in patients with a first VTE. In a sex stratified analyses, history of MI was a risk factor for 
VTE recurrence in women but not in men. The 5-year cumulative incidence of recurrence in men with 
and without prior MI was similar. Our findings suggest that a history of MI is a persistent risk factor for 
VTE recurrence among women.  
The association between prior MI and VTE recurrence, and possible mechanisms behind this 
association in a cohort of patients with incident VTE has not been extensively studied. Although several 
population-based studies (68, 147, 151, 152, 218), and an individual-level data meta-analysis (219) 
have shown a link between cardiovascular events and risk of incident VTE, there are no reports 
describing history of MI and risk of VTE recurrence among patients with first VTE.  
In general, our study found that patients with a history of MI had a 45% increased risk of VTE 
recurrence. Analysis of a randomized controlled trial database involving 1021 patients with VTE (750 
with DVT and 271 with PE) who were followed up for 3 months after the start of anticoagulation 
therapy demonstrated that presence of chronic cardiovascular disease in patients with symptomatic 
VTE was associated with a 2-fold increased risk of recurrent VTE during the initial 3 months of 
anticoagulant therapy (154). This study did not report sex-stratified results. As shown in Paper III, 
patients with a first VTE related to hospitalisation due to medical illness (without cancer or surgery) 
had a high risk of VTE recurrence even after competing risk of death was taken into account (220).  
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In our study, the risk of VTE recurrence in women with a history of MI was 2.5 times higher 
than in those with no history of MI, whereas a weak association was observed in men. A 
hypercoagulable state is found to play a vital role in the development of arterial events in younger 
subjects (221, 222). Our findings of a high recurrence risk in female VTE patients with a history of MI, 
suggests that a hypercoagulable state may play an important role also in the pathogenesis of MI in 
these patients. Another potential mechanism may be an inflammation. Investigators of The Tromsø 
Study reported that high levels of C-reactive protein (CRP) were associated with VTE risk particularly 
in women, and that chronic low-grade inflammation may be a potential common pathway for MI and 
VTE in obese women (223). Due to their stronger innate inflammatory response, women are at higher 
risk of developing autoimmune diseases than men (224). Women with autoimmune diseases such as 
SLE and rheumatoid arthritis have increased risk of cardiovascular events (225, 226), and these 
autoimmune disorders may predispose for both MI and VTE (214).  
Studies have shown that risk of VTE recurrence is higher in men compared with women (127, 
134, 136) and men have higher baseline risk for MI (185, 227). In our study, the crude IRs of recurrent 
VTE according to MI exposure were almost similar among men and women (5.1 and 6.5 per 100 PY, 
respectively). However, the baseline risk of recurrence in those without MI was higher in men (IR=4.1) 
than women (IR=1.9). The absolute incidence rate difference per 100 PY was 4.6 in women and 1.0 in 
men. The higher baseline risk of recurrence among men without a history of MI shows that men are at 
higher risk of recurrence also due to other risk factors. Thus, history of MI may be a persistent risk 
factor for VTE recurrence among women with first VTE, whereas it could not be used to distinguish 
between men at high and low risk of recurrence. Due to the limited statistical power in subgroup 







I. The rate of VTE has not decreased during the last decades. Our findings indicate that VTE 
remains a major public health challenge. Future research should focus on improving risk 
stratification and prevention of VTE in order to reduce the burden of VTE in the society. 
 
II. Despite advances in VTE management during the last decades, the rates of adverse events 
remained high especially in the first year following a VTE. VTE recurs frequently, and this trend 
continues for at least 10 years and possibly longer after the incident event. In order to reduce the 
disease burden associated with VTE, future studies should focus on development of risk 
prediction models with high precision in order to identify high-risk individuals with a favourable 
benefit-to-harm ratio for anticoagulant treatment. 
 
 
III. The risk of recurrence after a hospital-associated first VTE appeared to be dependent on the 
reason for hospitalization. However, except for surgery-related VTE, this did not hold true in the 
competing risk analysis. Our findings suggest that patients suffering from incident VTEs 
associated with hospitalization for medical illness other than cancer or surgery have a high risk of 
recurrence, even after competing risk by death is taken into account.  
 
IV. In conclusion, a history of MI was associated with increased risk of VTE recurrence in women, 
whereas no association was observed in men. Our findings suggest that MI may be a persistent, 
rather than transient, risk factor for VTE in women. Our findings must be interpreted with caution 




7. Implications of results and future perspectives 
The results from Papers I and II of this thesis confirm that the disease burden of VTE remains 
substantial. The incidence rates of VTE has increased over the last decades, and the rates of adverse 
events remain high, especially in the first year following a VTE.  
Although the introduction of better diagnostic tools to some extent may explain the increase 
in PE rates, our findings suggest that there is still a need for improvement in risk stratification and 
prevention strategies for first time VTE. Identification of novel, preferably modifiable, risk factors at 
the population level is of high importance to reduce the incidence of VTE. Moreover, future studies 
should focus on identifying risk factors that can contribute to improved risk stratification of patients in 
high-risk situations (e.g. surgery or hospitalization for acute medical conditions), so that targeted 
thromboprophylaxis can be better utilized with a favourable benefit-to-harm ratio. 
Predicting the risk of recurrence in an individual patient is a challenge. Episodes of VTE are 
often categorized as provoked or unprovoked, and this categorization has implications for risk of 
recurrence and treatment duration. However, this categorization is not always clear-cut.  For instance, 
hospitalization may be considered as a provoking factor for first VTE. However, in Paper III we show 
that the risk of recurrence is highly dependent on the reason for hospitalization, as patients with a first 
VTE related to hospitalisation for medical illness other than cancer or surgery have a high recurrence 
risk, whereas those with a surgery-related first VTE have a low recurrence risk.  Further, we show that 
women with a history of MI have an increased risk of recurrence (Paper IV), which suggests that MI 
may not be a considered purely as a transient provoking factor in women. In general, there is still a 
need to investigate risk factors for VTE recurrence. Currently existing risk prediction models for 
recurrence should be improved, or new models should be developed. Our studies show that in 
conditions with a high mortality rate, the cumulative incidence of recurrence is overestimated with 
conventional survival analyses. Future studies with predictive purposes should therefore consider to 
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